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The Effects of a Structured Adherence Intervention to HAART on Adherence and  
 
Treatment Response Outcomes 
 
Donald E. Kurtyka 
ABSTRACT 
Background:  Adherence to antiretroviral (ARV) medications in excess of 90-95% 
is necessary for optimal response to suppress HIV replication and to maintain and/or 
restore immune function.   A number of interventions have been shown to improve ARV 
adherence, but no research has been conducted which evaluates proactive monitoring of 
pharmacy refill adherence and subsequent intervention when inadequate adherence is 
identified.  
Purpose: The purpose of this project was to compare treatment response, 
pharmacy refill adherence and self-reported medication adherence between two groups of 
patients: those participating in an AIDS Drug Assistance Program (ADAP) and those 
participating in a Medicaid-funded medication access program.  The ADAP served as a 
structured adherence intervention (SAI) based on procedural and administrative processes 
required by the state-managed program.  Additionally, covariates that can impact 
adherence were studied including utilization of adherence services and interventions and 
factors related to HIV disease, antiretroviral agents and sociodemographic factors. 
 Method:  This retrospective comparative study examined secondary data to assess 
424 patients who received clinical and pharmacy services at one treatment site in 2005.   
xi 
 
 
Analysis: Logistic regression was performed to test the effects of the SAI on 
treatment response (CD4 and HIV RNA response), self-reported adherence, and 
pharmacy refill adherence while controlling for the covariates.  
Results:  Patients participating in the SAI demonstrated higher levels of both self-
reported and pharmacy refill adherence compared to patients receiving usual care.  
Although patients participating in the SAI program demonstrated better virologic (HIV 
RNA) responses to HAART compared to patients receiving usual care, immunologic 
(CD4 lymphocyte) responses to HAART were not significantly different compared to 
subjects in the usual care program. 
Conclusion/Discussion:  This study provides information on the effects of a 
structured programmatic intervention on medication adherence and response to treatment 
and will be used to inform policy decision making at the local and State level.   
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CHAPTER ONE: INTRODUCTION 
Background 
 Human immunodeficiency virus (HIV) infection was originally considered a 
terminal illness when identified in the early 1980s.  Nearly everyone who contracted the 
disease advanced to Acquired Immunodeficiency Syndrome (AIDS) and death (Bartlett 
& Gallant, 2005).  Treatment with the first antiretroviral agent zidovudine (AZT), which 
became available in the late 1980s, gave short-term encouragement to those with HIV 
disease.  Within a year, however, most persons no longer responded to this medication 
and became ill or died.  A breakthrough occurred in 1996 with the introduction of an 
effective combination therapy capable of suppressing HIV replication.  These potent 
combination drug regimens now known as highly active antiretroviral therapy (HAART) 
redefined HIV disease into a chronic illness requiring long-term management rather than 
a terminal disease (Johnson et al., 2006).  During the last decade, advances in the 
scientific understanding of  HIV dynamics and pathogenesis, the development and 
widespread use of quantitative HIV ribonucleic acid (RNA) assays to quantify serum 
levels of HIV, and the availability and use of powerful antiretroviral agents culminated in 
dramatic changes in HIV clinical care and improved clinical outcomes (Williams et al., 
2006).   
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Adherence 
The World Health Organization (2003) broadly defined adherence as the extent to 
which a patient's behavior, such as taking prescribed medications or following a diet, 
corresponds with the interventions of the healthcare provider.  Medication adherence in 
HIV disease has been defined as the ability of the person living with HIV/AIDS to be 
involved in choosing, starting, managing and maintaining a combination medication 
regimen to control viral replication and improve immune function (Jani, 2002).   The 
terms adherence and nonadherence are meant to be nonjudgmental, statements of fact 
rather than expressions of blame toward the patient or provider (Bangsberg, Perry et al., 
2001).   
Highly Active Antiretroviral Therapy (HAART) 
Antiretroviral (ARV) drugs for the treatment of HIV disease are broadly classified by 
the phase of the HIV lifecycle that the drug inhibits. Antiretroviral drugs currently 
licensed for clinical use by the Food and Drug Administration are classified as 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse 
transcriptase inhibitors (NNRTI), protease inhibitors (PI), and entry inhibitors (EI). Table 
1 lists these agents by classification and mechanism of action.    
HAART is the combination of at least three ARV drugs that target at least two 
different parts of the HIV lifecycle or stop the virus from entering CD4 lymphocytes.  A 
panel of experts convened by the Department of Health and Human Services regularly 
publishes guidelines suggesting preferred and alternative combinations that can be 
combined to form a HAART regimen.  HAART typically includes two NRTIs paired 
with an NNRTI or a PI.  In advanced stages of HIV disease or when significant 
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medication resistance is present, HAART regimens may include more than four or five 
agents (National Institutes of Health, 2006). 
 
Table 1 
FDA Approved Antiretroviral Agents 
 
 
Classification 
 
Mechanism of Action 
 
Agents 
Nucleoside and nucleotide 
reverse transcriptase inhibitors 
(NRTI) 
The reverse transcription process is blocked. 
HIV RNA cannot be converted to HIV DNA 
and viral reproduction is terminated. 
Zidovudine 
Lamivudine 
Stavudine 
Entricitabine 
Didanosine 
Tenofovir 
Abacavir 
 
Non-nucleoside reverse 
transcriptase inhibitors (NNRTI) 
The reverse transcription process is blocked. 
HIV RNA cannot be converted to HIV DNA 
and viral reproduction is terminated. 
Nevirapine 
Efavirenz 
Delavirdine 
 
Protease inhibitors (PI) Final viral assembly is inhibited when protease 
enzymes are not available to reassemble viral 
particles and produce new virus. 
Saquinavir 
Ritonavir 
Nelfinavir 
Indinavir 
Lopinavir/ritonavir 
Atazanavir 
Fosamprenavir 
Tipranavir 
Darunavir 
 
Entry Inhibitors  The process of HIV binding to a CD4 
lymphocyte is interrupted, thus blocking the 
ability of HIV to infect a CD4 lymphocyte. 
Enfuvirtide 
Maraviroc 
 
 
 
Effects of HAART on Outcomes 
The introduction of HAART has dramatically decreased morbidity and mortality 
among HIV-infected patients throughout the developed world (Egger et al., 1997; Hogg 
et al., 1998; Palella et al., 1998).  In the United States, mortality from HIV infection 
decreased by 70% between 1996 and 1998 and decreased an additional 14% between 
1998 and 2002 (Centers for Disease Control, 2004; Frick, Tapia, Grant, Novotny, & 
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Kerzee, 2006; Hogg et al., 1998; Palella et al., 1998).  The incidence of opportunistic 
infections associated with AIDS has also decreased significantly with the use of HAART 
(Grabar et al., 2000). 
Patients’ ability to adhere to complex regimens is an essential component of 
successful antiretroviral therapy (Kitahata et al., 2004) and is widely regarded as the most 
important mutable determinant of clinical outcomes in the HIV-infected patient (Wood et 
al., 2003).  Although a decrease in the number of CD4 lymphocytes is the strongest 
predictor of progression to AIDS and death, adherence to HAART is the second most 
common predictor (Bangsberg, Perry et al., 2001; Garcia de Olalla et al., 2002; Hogg et 
al., 2002; Machtinger & Bangsberg, 2006; Wood et al., 2004).  In studying levels of 
adherence, Bangsberg and his team (2001) found that no patients in a group of highly 
adherent patients developed AIDS-defining events over the 16 months of the study 
compared to those with moderate and low adherence.  Each 10% difference in mean 
adherence was found to be associated with a 28% reduction in risk of progression to 
AIDS.  Another group concluded that adherence behavior is a dynamic process and 
continued adherence was associated with improved response to ARV therapy (Carrieri et 
al., 2001). It has been estimated that a nonadherent patient receiving HAART is 3.87 
times more likely to die than an adherent patient on the same therapy (Garcia de Olalla et 
al., 2002). 
Although adherence to HAART at a level above 95% has been associated with 
optimal viral suppression, the relationship between various levels of adherence, resulting 
virologic treatment responses, and long-term clinical outcomes has not been determined.  
Previous studies have examined relatively small numbers of patients in relation to short-
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term virologic response to HAART.   Adherence to antiretroviral therapy in both the 
short-term and the long-term is crucial for treatment success and must be continually 
reinforced (Hammer et al., 2006).  
Difficulty Adhering to HAART / Nonadherence 
Overview and Implications 
The Department of Health and Human Services (DHHS) develops and publishes 
HIV treatment guidelines on a regular basis.  These guidelines reinforce that one of the 
most important issues in managing patients receiving HAART is adherence to therapy 
(National Institutes of Health, 2006).  When treating HIV disease, adherence levels need 
to be at the 90-95% level to achieve and maintain therapeutic effectiveness (Murphy, Lu, 
Martin, Hoffman, & Marelich, 2002; Paterson et al., 2000).  Maintaining this threshold 
can be complex and difficult.  Adherence to HAART has been described as the 
“Achilles’Heel” of antiretroviral therapy (Simoni, Frick, Pantalone, & Turner, 2003) 
because of the difficulty associated with maintaining such high levels of medication 
adherence.  
There are a number of contributing factors that make 100% adherence to HAART 
difficult for many patients including the complexity of the HAART regimen (multiple 
pills, multiple doses, food requirements and restrictions), immediate and long-term side 
effects associated with the ARV agents, and comorbid conditions such as active 
substance abuse and mental illness. 
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Prevalence of Nonadherence 
Nonadherence to medication therapy has been a problem for as long as remedies 
for health conditions have been prescribed (Chesney, 2006).   Evidence shows that poor 
adherence to ARV regimens has serious consequences for HIV-infected patients including 
failure to prevent viral replication, an increased likelihood of developing viral resistance,  
decreasing CD4 lymphocyte counts, ineffective disease treatment, increasing illness, 
advancement to AIDS, and ultimately death (Bangsberg, Hecht et al., 2001; Gifford et al., 
2000; Miller & Hays, 2000a; Murphy, Lu, Martin, Hoffman, & Marelich, 2002; Turner, 
2002).  Despite these risks, nonadherence to HAART is widespread in the United States 
and in Europe with estimates of the percentage of prescribed doses taken ranging from 
60% to 70% (Bangsberg et al., 2000; Bartlett, 2002; Gordillo, del Amo, Soriano, & 
Gonzalez-Lahoz, 1999; Martin-Fernandez, Escobar-Rodriguez, Campo-Angora, & 
Rubio-Garcia, 2001; Moatti et al., 2000; Nieuwkerk et al., 2001).  
The average rate of adherence varies by the method used to assess it and the 
group studied.  In one prospective study, 140 individuals in a public U.S. hospital HIV 
clinic were followed for one year after initiation of HAART. The investigators assessed 
adherence using three methods and calculated a composite adherence rate of only 71%.  
Only six percent of the patients took at least 95% of their medications, the optimal level 
for durable virologic and clinical success (Golin et al., 2002). Studies of different groups 
of HIV-positive individuals in the United States and abroad generally show similar, 
suboptimal rates of adherence (Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; 
Knobel et al., 2001; Murri et al., 2000; Walsh, Mandalia, & Gazzard, 2002).  Rates of 
adherence are known to decline over time.   Most patients taking HAART, regardless of 
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their background or life situation, will encounter difficulties with adherence at some point 
(Howard et al., 2002; Mannheimer, Friedland, Matts, Child, & Chesney, 2002). 
Inadequate adherence may eventually undermine the dramatic improvements in 
HIV-related health parameters seen in resource-rich countries and the expected response 
in developing countries as HAART becomes more widely available.  Not only can 
nonadherence negatively impact clinical outcomes, it can add significantly to the cost of 
care.  It was, however, the recognition that nonadherence results in transmittable forms of 
drug resistant strains of HIV that brought attention to the problem rather than suboptimal 
clinical outcomes (Chesney, 2006). 
Although most experts accept that adherence to antiretroviral medication is 
critical to the effectiveness of HIV treatment (Bangsberg et al., 2000; Haubrich et al., 
1999; Liu et al., 2001), few rigorously designed studies have documented the efficacy of 
interventions to improve adherence to ARV treatment (Williams et al., 2006).  While the 
potency of current therapeutic options for treatment of HIV disease has decreased 
morbidity and increased survival, imperfect adherence to HAART remains a major cause 
of treatment failure among patients with HIV disease (McNabb et al., 2001) (Palella et 
al., 1998; Paterson, Potoski, & Capitano, 2002).   
Impact of Adherence 
 Highly active antiretroviral therapy has resulted in a longer life during the chronic 
stage of HIV infection.  The Swiss HIV cohort study initially documented this trend, 
showing an increase in the survival rate from 19% in 1991 to 62% in 1996 (Egger et al., 
1997).  Recent projections published in 2006 estimated that the life expectancy of 
someone currently beginning care for treatment of HIV is at an all-time high of 24.2 
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years (Schackman et al., 2006).  It is imperative that research be conducted to more fully 
understand adherence and to identify evidence-based interventions that can be developed 
and implemented to improve patient outcomes in people living with HIV disease. 
Factors Associated with Nonadherence 
Adherence to medication is a complex behavior which is influenced by many 
factors related to the patient, the prescribed treatment, the disease state, the healthcare 
provider and patient-healthcare provider relationship, and the healthcare system. Many 
studies have yielded discordant results, making it difficult to achieve consensus on 
modifiable barriers and predictors on which adherence intervention strategies should be 
designed (Ammassari et al., 2002).    Some of these factors are immutable such as age, 
income, literacy, and the patient's social milieu while other factors are potentially 
alterable, such as depression, substance abuse, regimen complexity, medication side 
effects, and the therapeutic relationship between patient and provider.   
 Patient Factors 
Patient factors affecting adherence include the sociodemographic factors of age, 
gender, race/ethnicity, income, education, literacy, housing status, insurance status, and 
risk factor for acquisition of HIV infection.  Psychosocial factors typically encompass 
mental health issues, substance use, social climate and support, knowledge and attitudes 
about HIV and its treatment).   Additionally, patients have identified many diverse 
reasons for missing their medications. Gifford and his colleagues (2000) found that 
organizational difficulties (e.g., too busy, forgot, away from home, change in routine) and 
emotional issues were the most common reasons for missed doses. 
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Conflicting results have been reported regarding the association between 
sociodemographic factors and adherence behavior. When an association was found, the 
direction was consistent: younger age, non-white race/ethnicity, lower income, lower 
literacy, and unstable housing were negatively associated with adherence in resource-rich 
settings. Gender, educational level, insurance status, and HIV risk factors generally were 
not associated with adherence behavior (Altice, Mostashari, & Friedland, 2001; Gifford 
et al., 2000; Golin, Isasi, Bontempi, & Eng, 2002; Haubrich et al., 1999; Holzemer et al., 
1999; Kleeberger et al., 2001; Mannheimer, Friedland, Matts, Child, & Chesney, 2002; 
Paterson et al., 2000).   
Psychosocial Factors   
More consistent associations were found between certain psychosocial factors and 
adherence behavior.  Common predictors of less than adequate adherence include 
untreated depression, other psychiatric morbidity such as anxiety and bipolar disease, 
stressful life events and lack of social and family support (Ammassari et al., 2001; Cinti, 
2000; Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Holzemer et al., 1999).  
Active substance abuse including cocaine, marijuana, amphetamines, sedatives, and 
moderate to heavy alcohol consumption have also been inversely linked to adherence 
(Golin et al., 2002). Patients who are unable to correctly identify their drug regimen or 
describe the relationship between adherence and drug resistance are also more likely to 
be nonadherent.  Belief in the efficacy of the medication and the presence of social 
support systems has been positively related to adherence to HIV (Ammassari et al., 2002) 
(Miller et al., 2003; Stone et al., 2001; Tucker, Burnam, Sherbourne, Kung, & Gifford, 
2003).   
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Treatment Related Factors  
 Factors related to the treatment regimen can impact adherence including the 
number of pills prescribed, complexity of the regimen including dosing frequency and 
food instructions and restrictions, convenience of the regimen, type of ARV agents 
prescribed (e.g. protease inhibitor vs. non-nucleoside reverse transcriptase-based), side 
effects associated with the agents and the ability to incorporate the regimen into an 
individual's daily routine (Bartlett, 2002; Chesney, 2000; Walsh, Mandalia, & Gazzard, 
2002).  In general, adherence declines with the emergence of side effects.  Side effects 
associated with HAART are common and include transient events such as diarrhea, 
nausea and fatigue as well as longer-lasting adverse effects such as metabolic disorders 
including diabetes and lipid disorders, lipodystrophy and neuropathy (Chesney, 2003).  
With regards to HAART, side effects are the primary cause of nonadherence and account 
for more regimen changes than do treatment failures (Ammassari et al., 2001). 
The association between the number of doses per day and patient adherence is 
well described, with adherence declining as dosing frequency increases (Bartlett, 
DeMasi, Quinn, Moxham, & Rousseau, 2001; Claxton, Cramer, & Pierce, 2001). High 
pill burden has been reported as a primary reason for missing or discontinuing HAART 
(Bartlett, DeMasi, Quinn, Moxham, & Rousseau, 2001; Trotta et al., 2002).  With the 
continued development of newer antiretroviral treatment agents, attention has focused on 
improving the efficacy, convenience and tolerability of medications with particular 
emphasis placed on reducing pill burden and dosing frequency.  Data are emerging that 
demonstrate a positive association on adherence with once daily HAART regimens 
(Johnson et al., 2006).   
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Bartlett (2001) identified pill burden as the most significant predictor of HAART 
response.  Since that time, treatment regimens have continually been simplified.  In 2006, 
a one-tablet, once-daily HAART regimen became available and greatly reduced the 
scheduling requirements and pill burden associated with HAART (U.S. Food and Drug 
Administration, 2006).  In a meta-analysis of 23 clinical trials involving 3,257 patients to 
determine predictors of virologic suppression, researchers found pill burden to be the 
most significant predictor of antiretroviral response (Stone et al., 2001).  Although once-
daily regimens demonstrated improved attainment of virologic control in two large RCTs 
that compared once-daily with twice-daily regimens, it is not clear if the benefit seen with 
once-daily HAART resulted from increased potency of the regimens studied, better 
adherence, or both (Molina, Ferchal, & Rancinan, 2003) (Raffi, Saag, & Cahn, 2003; 
Saag, Cahn, & Raffi, 2002).  Data from additional studies related to this issue are 
expected in the near future. 
Stone et al. (2001) conducted a cross-sectional survey of women and found that 
self-reported adherence was better among patients with less complex HAART regimens 
due in part to the fact that patients’ understanding of regimen dosing decreases as 
regimen complexity increases.  Therefore, simplifying HAART regimens may have an 
important role in improving patients’ adherence.  Conversely, increasing complexity in 
the medication regimen is associated with decreasing patient adherence. 
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Disease Characteristics 
Disease characteristics affecting adherence include the stage and duration of HIV 
infection, HIV-related symptoms and AIDS-associated opportunistic infections.  
Adherence rates are consistently lower for a long term, chronic illnesses and for 
asymptomatic conditions (Graney, Bunting, & Russell, 2003).  Over time, even the most 
motivated patients may find it increasingly difficult to remain adherent (Ickovics et al., 
2002).   
Asymptomatic HIV-infected patients may be less adherent since the only 
immediate perceived effect of HAART may be deterioration in health status and well-
being as a result of medication side effects and disruptions in daily routine.  Certain 
patterns of behavior in patients with chronic, asymptomatic illness have been linked to 
nonadherence including not filling prescriptions, forgetting doses, taking incorrect doses, 
stopping medication too soon, and self-regulating the regimen to manage side effects 
(Ammassari et al., 2002; Chesney, 2003; Hubbard, 2006; Trotta et al., 2002).     
Conversely, Williams (1999) found that adherence is frequently greater in patients 
with advanced HIV disease as the improvement in disease-related symptoms resulting 
from controlling viral replication with HAART often outweighs the adverse effects of 
treatment.  Increased adherence was seen in patients with opportunistic infections.  The 
researchers believed this was explained by the patients’ desire for improved health and a 
stronger motivation to adhere.  Several studies described a relationship between HIV-
related symptoms and nonadherence (Holzemer et al., 1999; Wagner, 2002).  
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Holzemer and colleagues (1999) found that clients with higher symptom scores, 
particularly depression, were more likely to be nonadherent to medication, not to follow 
provider advice, and to miss appointments while those who reported having a meaningful 
life, feeling comfortable and well cared for, using their time wisely, and taking time for 
important things were both more adherent to their medications and more likely to follow 
provider's advice.  They suggested that strategies to enhance adherence should include 
recognition and treatment of symptoms (particularly depression) and an understanding of 
clients' perceptions of their environment. 
Patient-Provider Relationship and Social Support 
Several studies have documented that positive relationships with friends, family 
and healthcare providers can impact adherence to medication.  Researchers found that a 
positive patient-provider relationship can be an important motivating factor for taking and 
adhering to HAART.  Factors that have been identified as strengthening patient-provider 
relationships include communication quality and clarity, compassion, willingness to 
include patients in treatment decisions, adequacy of referrals, and convenience of visiting 
the provider. Conversely, frustration for providers has been associated with lack of 
adherence to treatment, missed appointments, complexity of treatment regimens and 
medication side effects (Ammassari et al., 2002; Chesney, 2000).  
Health beliefs, coping skills and rapport with healthcare providers have been 
correlated with adherence to HAART.  Patients are more likely to be adherent if they 
have confidence in, and guidance from, their healthcare providers (Bertholon, Rossert, & 
Korsia, 1999; Holstad, Pace, De, & Ura, 2006).  The patient's overall satisfaction and 
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trust in the provider and clinical staff along with the patient's opinion of the provider's 
competence, willingness to include the patient in the decision-making processes, the 
adequacy of referrals and the convenience of visiting the provider can affect adherence 
(Ammassari et al., 2002; Chesney, 2000; Stone et al., 1998).  
Findings from two studies suggested an association between stressful life events 
and nonadherence (Gifford et al., 2000; Moatti et al., 2000). Lack of social or family 
support and poor self-efficacy have also been found to be an important risk factor for 
nonadherence (Altice, Mostashari, & Friedland, 2001; Catz, Kelly, Bogart, Benotsch, & 
McAuliffe, 2000; Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Murri et al., 
2002; Stone et al., 1998).  Ammassari and colleagues (2002) concluded that the presence 
of tangible and emotional support can reduce barriers and increase motivation for 
adherence. 
Lucas et al. (2004) found that patients who kept medical appointments were more 
likely to be adherent to medication. Additionally these researchers found that adherence 
was associated with patients’ understanding that suboptimal adherence leads to resistance 
and a recognition that taking all medication doses is critically associated with adherence.  
It has been suggested that members of the healthcare team work in partnership with 
patients and to involve representatives from the entire HIV community to strengthen 
collaborative efforts related to the promotion of adherence (Chesney, 2000). 
Environmental Factors:  The Healthcare System 
Research addressing the relationship between the healthcare setting and adherence 
behavior are limited. Chesney (2000) found that aspects of the clinical setting can 
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positively impact adherence such as easy access to ongoing primary care and 
convenience in scheduling appointments, involvement in a dedicated adherence program, 
availability of transportation and child care services, comfort with the clinical 
environment, perceived confidentiality, and satisfaction with past experiences in the 
healthcare system.   Conversely, dissatisfaction with experience in the healthcare system 
has been associated with nonadherence.  Women studied by Powell-Cope and colleagues 
(2003) identified difficulty obtaining medication refills and concerns related to 
confidentiality as barriers to adherence.    
Conclusions 
 Adherence to highly active antiretroviral therapy is strongly correlated with both 
immunologic and virologic success, as evidenced by decreased HIV RNA levels and 
increased CD4 lymphocyte counts.  Unfortunately, achieving and maintaining high levels 
of adherence to complex HAART regimens can be very difficult (Bangsberg et al., 2000; 
Haubrich et al., 1999). The reasons for inadequate adherence are complicated and often 
involve many variables related to the medications, co-morbid health conditions, 
environmental barriers and psychosocial concerns.  Consequently, successful HAART is 
often limited due to inadequate medication adherence (Carpenter, 1997; Knobel et al., 
2001).   
 Experts in the field of HIV have come to consensus on the importance of adequate 
adherence to HAART (Bangsberg & Deeks, 2002) (Chesney, 2003; Paterson et al., 
2000).  Despite the importance of this subject, empiric research on adherence 
interventions for HIV-infected individuals is minimal.  Simoni and colleagues (2003) 
described adherence research as being in the embryonic stage.   In their 2004 adherence 
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supplement, the DHHS guidelines concluded that interventions to improve adherence for 
HAART are insufficiently characterized and understood, and additional research 
regarding the topic needed (National Institutes of Health, 2004).  Berg and Arnsten 
stressed that adherence measurement is needed in clinical and research settings, and 
called for research to evaluate methods and provide recommendations for research and 
clinical care (Berg & Arnsten, 2006). 
The importance of adherence is demonstrated by the integration of adherence 
recommendations into national consensus guidelines for the use of HAART antiretroviral 
therapy (National Institutes of Health, 2006).  While more adherence research is called 
for, methodological barriers are evident. Uncertainty exists regarding the best measure of 
adherence in both clinical practice and in research settings.  Patient report, pill counts, 
and provider estimates may overestimate adherence, while electronic methods such as the 
Medication Event Monitoring System (MEMS) frequently underestimate ARV 
adherence, are too costly, and are not practical for use in routine clinical care.  
Furthermore, the process of monitoring patients behavior when measuring adherence may 
act as an intervention that changes adherence (Turner & Hecht, 2001).  
Statement of the Problem 
Adherence to HAART has arisen as one of the most important issues in the 
effective treatment of HIV disease.  The difference in long-term viral suppressive 
response between those who take their medicine correctly 90-95% of the time and those 
who do not, can be the difference between life and death (Paterson et al., 2000).    The 
identification of effective and clinically practical adherence interventions could greatly 
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improve the response to treatment modalities. For this reason, it is critical to determine 
interventions that promote adherence. 
Purpose of the Study 
The purpose of this retrospective comparative study was to evaluate the effects of 
a structured adherence intervention (SAI) as a component of an existing antiretroviral 
access program on adherence to HAART and response to treatment as compared to usual 
care.  In the structured adherence intervention providers closely monitored monthly HIV 
medication refills and provided structured adherence intervention when indicated.  
Patients receiving usual care were enrolled in a Medicaid-funded medication access 
program and did not receive ongoing medication refill monitoring and structured 
adherence intervention.  Both patient groups received their ARV medications and 
outpatient HIV medical care from a single treatment center and pharmacy. 
Specific Study Aims and Research Questions 
Study Aim 1:  To determine whether patients participating in the SAI program 
experienced higher levels of adherence compared to patients receiving usual care, 
controlling for adherence services and intervention, HIV disease-specific factors, ARV-
specific factors, and sociodemographic factors. 
Research questions: 
1a. Is there a difference in self-reported adherence in subjects participating in 
the SAI program compared to those who receive usual care? 
1b. Is there a difference in pharmacy refill adherence in subjects participating 
in the SAI program compared to those who receive usual care? 
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Study Aim 2:  To determine whether patients participating in the SAI program 
experienced improved response to treatment compared to patients receiving usual care, 
controlling for HIV disease-specific factors, ARV-specific factors, and sociodemographic 
factors. 
Research questions: 
2a. Is there a difference in CD4 lymphocyte response in subjects participating 
in the SAI program compared to those who receive usual care? 
2b. Is there a difference in HIV RNA response in subjects participating in the 
SAI program compared to those who receive usual care? 
Hypotheses 
1. Patients participating in the SAI will have higher levels of self-reported and 
pharmacy refill adherence compared to patients receiving usual care, controlling 
for covariates. 
2. Patients participating in the SAI program will have better immunologic (CD4 
lymphocyte) and virologic (HIV RNA) responses to HAART  compared to those 
receiving usual care, controlling for covariates. 
Significance of the Study 
Although a great deal of progress has been made in the measurement of 
medication adherence in HIV disease and evaluation of adherence interventions, 
additional work is still needed.  Ongoing research is needed to develop and validate 
accurate, practical and cost-effective methods for measuring adherence to HAART that 
can be used in both developing and industrialized countries.  Study samples should 
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include more racial and ethnic minorities and women to more accurately represent the 
current population with HIV disease.   
Despite the importance of adherence related to HAART, empiric research on 
adherence interventions for HIV-infected individuals is minimal.  Although several 
researchers have studied self-reported and pharmacy refill adherence, there are no 
published studies of medication access programs that proactively monitor pharmacy 
refills and initiate adherence interventions when adherence deficiencies are identified.  
This study is designed to further the existing knowledge with relation to these additional 
variables.  The findings will provide information on the effects of a programmatic 
intervention on medication adherence and response to treatment that can be used to 
inform policy decision making at the local, regional, and state levels.    
Summary 
This chapter presented the importance of adherence related to HAART and the 
need to identify effective interventions to foster adherence.   High levels of adherence to 
HAART are necessary for optimal response to therapy.   Optimal response to HAART 
results in improved viral suppression, improved immunologic response and functioning, 
and ultimately a decrease in morbidity and mortality. Nonadherence remains strongly 
associated with mortality (Wood et al., 2003).  Limited research studies have identified 
effective interventions which can improve adherence. 
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CHAPTER TWO: REVIEW OF THE LITERATURE 
 
 
Introduction 
This chapter includes a review of research related to the measurement of 
adherence to HAART in HIV disease and interventions to increase or strengthen 
adherence to HAART.  Although adherence to HAART is the strongest predictor of HIV 
viral suppression, drug resistance, disease progression and death in HIV-infected 
individuals, there is no standard approach to adherence assessment and intervention in 
routine clinical practice. 
Definition of Adherence 
HAART adherence researchers have yet to identify a standardized definition of 
adherence and few studies use consistent measures of adherence. Therefore adherence 
data must be interpreted with caution and comparison among studies is difficult (Hill, 
Kendall, & Fernandez, 2003; Powell-Cope, Toney, & Montano, 2001).  One study may 
define adherence as the percentage of prescribed doses taken within two hours of 
scheduled dosing time over a 1-week period according to electronic data monitoring 
(EDM) while another may operationalize adherence as the percentage of prescribed doses 
taken in the last month according to self-report.  Adherence studies are also inconsistent 
with regard to measurement of clinical outcomes.  Some studies reported immunologic 
effects in terms of CD4 lymphocyte response while others reported virologic outcomes in 
terms of HIV RNA response.  Some studies reported both immunologic and virologic 
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outcomes while others do not address either of these outcome measurements (Simoni, 
Pantalone, Frick, & Turner, 2005).  Holzemer et al. (1999) even expanded the concept of 
adherence beyond only medication adherence to include following clinician instructions 
and missed appointments. 
Measurement of Adherence 
Adherence to HAART is a complex issue involving social, cultural, economic and 
personal factors.  This complexity makes it difficult to identify a reliable and valid single 
measure of adherence that is appropriate for all settings (Chesney, 2006).  Research and 
clinical care have also been hindered by the lack of an inexpensive, quick and accurate 
method to measure adherence (Dunbar-Jacob & Mortimer-Stephens, 2001).   
Chesney (2006) argued that it may be impossible to develop a “gold standard” definition 
of adherence and a standard measurement of adherence as the HIV epidemic is too 
diverse throughout the globe.   
Introduction 
Clinical studies employ a number of methods, alone or in combination, to 
measure medication adherence.  A number of studies have shown, however, that the 
objective measures used in research, although impractical for most clinical settings, are 
more sensitive than patient self-report for detecting medication adherence (Machtinger & 
Bangsberg, 2006).     
Adherence is usually measured as either a categorical or continuous variable.  
Two common approaches to defining a categorical outcome are to consider whether the 
patient missed any pills over a specific interval (such as the last 3 or 7 days) or whether 
the patient has exceeded a set percentage of doses taken (usually 95%).  This simplistic 
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dichotomous classification may not capture the complexity of adherence patterns such as 
adhering to timing of medication doses, medication-specific food requirements and 
taking the correct number of pills (Chesney, 2003).     
Measuring adherence as a continuous variable is less common in the literature 
than a dichotomous measure. When measured as a continuous variable, adherence is 
usually defined as the proportion of prescribed doses taken as measured by an electronic 
drug monitoring device, self-report, or pill count.  Adherence can also be measured as a 
continuous variable by obtaining the percentage of pills available for consumption by 
pharmacy refill records or the number of missed doses over a specified time period 
(Simoni, Pantalone, Frick, & Turner, 2005).  Many published studies simply reported the 
criterion for adherence as meeting the minimum level of drug consumption such as 
greater than 70, 80, or 90% (Fogarty et al., 2002). 
Adherence measurement is frequently classified as subjective (in the opinion of 
the patient) or objective (data recorded independently of the patient) (Orrell, 2005).  
Subjective approaches include self-report and self-administered questionnaires in which 
patients are asked to report the number of medications missed or taken based within a 
designated time frame.  Objective methods include electronic data monitoring (EDM) 
devices, pill counts and pharmacy refill data.  These various methods of measuring 
adherence will each be explored. 
Subjective Measures of Adherence 
Patient Self-Report 
Patient self-report offers a relatively inexpensive, simple and non-intrusive means 
of incorporating adherence data into routine clinical practice and the research setting. 
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Self-report is useful due to the relatively low cost, ease of administration and flexibility 
of use in a variety of settings (Bangsberg, Bronstone, Chesney, & Hecht, 2002). 
Although self-report is one of the most common methods of assessing medication 
adherence, inaccuracy may result due to imprecise or inconsistent questioning, patient 
forgetfulness and poor recall, or the patient’s desire to provide socially desirable 
responses along with a desire to please the healthcare provider and prevent criticism.   
Recall periods are inconsistent between studies (e.g. number of doses missed over the last 
3 days vs. the number of doses missed over the last 30 days).  Consequently, when self-
reporting methods are used to assess adherence, levels are frequently over-estimated.  
Although patients who admitted they have less than optimal adherence are almost 
always truthful, the reverse is not always true (Miller & Hays, 2000b).  Self-reported 
adherence was over-reported when compared to adherence measured by EDM in a study 
of 44 patients conducted by Melbourne and colleagues (1999).  Using an investigator-
designed questionnaire, patients self-reported an extraordinary amount of perfect 
adherence.  Using EDM data, patients under-reported their degree of deviation from their 
stated dosing times. 
A benefit of self-reported adherence measurement is the potential to reveal the 
reasons for missed or mistimed doses.  Considering that clinical, behavioral and 
psychosocial factors are among the most important factors that influence adherence 
(Chesney, 2003), self-report provides an opportunity to identify factors that might 
negatively affect adherence (Powell-Cope, Toney, & Montano, 2001). 
Researchers conducted a meta-analysis and found that self-reported measures 
reliably predicted clinical outcomes associated with adherence (Nieuwkerk & Oort, 
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2005).  This information is consistent with earlier studies that examined the relationship 
between self-reported adherence and virologic outcomes, protease-inhibitor drug levels 
and other clinical outcomes (Kerr, Walsh, Lloyd-Smith, & Wood, 2005).  While patient-
reported adherence has been consistently associated with viral suppression, as has 
adherence measured by EDM and unannounced pill count, self-reported adherence 
questionnaires or interviews used in research may fail to identify 20% to 28% of 
nonadherent patients (Bangsberg, Bronstone, & Hofmann, 2002).  
A number of studies have demonstrated a positive association between self-
reported adherence and HIV RNA suggesting that self-reports may be a valid indicator of 
adherence (Haubrich et al., 1999; Montaner et al., 1998).  Mannheimer and colleagues 
(2002) prospectively studied the correlation between self-reported adherence and 
successful response to HAART and found that a higher level of self-reported adherence 
over time was associated with better immunologic and virologic outcomes. While 
researchers concluded that self-reported medication adherence was a strong and 
independent predictor of virologic outcome, they also indicated that other methods of 
measuring adherence, such as the use of EDM, may allow for greater precision in 
measurement.  A recent meta-analysis confirmed that despite significant study 
heterogeneity, the pooled association between self-reported HAART adherence and HIV 
RNA was statistically significant (Nieuwkerk & Oort, 2005). 
The manner in which clinicians and researchers communicate with patients 
regarding adherence may impact the patient’s response.  Patients may provide more 
truthful information if the person collecting the data is not a direct member of the health 
care team or if the patient believes the data will not be reported to clinicians (Orrell, 
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2005).  Questioning, whether verbal or in writing, that is carefully structured, 
nonjudgmental, culturally appropriate, and posed in a nonjudgmental manner and with 
the use of permissive language may elicit the most accurate and truthful self-report data 
(Mannheimer, Friedland, Matts, Child, & Chesney, 2002).   An example might include: 
“Patients with complex medication schedules like yours often miss doses of their 
medications from time to time.  Can you tell me how many doses you missed in the last 
week?” An alternative might include: “Of the seven doses of medication you were 
prescribed to take last week, how many did you actually take?” (Melbourne et al., 1999).   
Patient self-report measures in the form of personal interviews or written 
questionnaires have many advantages including low cost, minimal participant burden, 
easy speed of administration, flexibility in terms of mode of administration and timing of 
assessment, and the potential to yield specific information about the timing of doses and 
adherence to food requirements.  The specificity of self-report measures is high, i.e., 
patients’ acknowledgment of nonadherence is generally credible (Bangsberg, Hecht et al., 
2001).   Self-report may not be feasible with some individuals such as the cognitively 
impaired (Simoni et al., 2006).  
Written medication diaries may increase the accuracy of self-report in patients 
who have difficulty remembering their pill-taking history.  A benefit is the relative low 
cost associated with this method.  However, one study suggested that patients did not 
consistently complete diaries and when they did, they tended to fill in the information 
immediately before a clinic visit. In one study utilizing diaries, only 25% of patients 
returned their diaries as instructed (Miller & Hays, 2000b).  Several other methods have 
been used to obtain self-report adherence levels including computer-assisted self- 
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interviews, visual analog scales, self-report instruments and questionnaires, and clinical 
assessment.  Each will be briefly discussed.  
Computer-Assisted Self-Interview 
Computer-assisted self-interview (CASI) technology may be an efficient way of 
obtaining self-reported data to identify HAART regimen errors and to monitor adherence. 
CASI involves a computerized interactive structured interview that assesses patients' 
understanding of HIV medication regimens and adherence levels. To minimize literacy 
requirements, patients can listen to an audio track which reads the interview text that 
normally would be presented visually on the computer screen. Photographs or graphics, 
rather than antiretroviral names alone, can be used to facilitate visual recognition of a 
patient's HAART regimen.  If performed in conjunction with a clinician appointment, the 
CASI data can be used to provide valuable teaching information as well as an assessment 
of adherence (Bangsberg, Bronstone, Chesney, & Hecht, 2002).    
CASI is time-efficient and may help detect nonadherence due to regimen errors or 
missed doses. In one study, CASI adherence assessment identified serious HAART 
regimen errors in up to 54% of patients. CASI-based adherence assessment can facilitate 
intervention by alerting clinicians to potential adherence problems, prompting a more 
detailed discussion of adherence during a clinical visit (Bangsberg, Bronstone, Chesney, 
& Hecht, 2002).  An adherence CASI has several additional advantages over traditional 
self-report methods.  Patients can be routinely and periodically assessed with a visual 
query of their understanding of, and adherence to, their HAART regimen with minimal 
use of clinician time. This may help to identify patients with regimen errors or in need of 
focused or intense adherence intervention.  Although there are expenses associated with 
   
 
 
 
27
initial start-up of this method, ongoing expenses are typically minimal.  Web-based CASI 
adherence assessment can be performed to identify difficulties with adherence more 
rapidly than otherwise possible with assessments that are only performed during actual 
clinic encounters. 
Visual Analog Scale 
Kalichman and his team (2005) used a pictographic visual analogue scale (VAS) 
to assess medication self-efficacy in a low-literacy population and found that the scores 
were associated with behavioral measures of medication adherence and HIV RNA 
response.  Visual analogue scales may be appropriate for patients with language 
challenges as well as those with reading limitations.   Giordano and his team (2004) 
compared an investigator-administered VAS in conjunction with a more complicated 3-
day medication recall instrument and unannounced pill counts in a group of marginally 
housed indigent patients who were on stable HAART regimens.  The VAS demonstrated 
good validity compared to unannounced pill count and HIV RNA, performed as well as 
the 3-day recall instrument and was easier to administer and answer than other recall 
instruments. 
The VAS method offers several advantages over the traditional recall method 
including decreased time requirement, ability to obtain data over a longer time frame and 
a lower response burden on the patient (Giordano, Guzman, Clark, Charlebois, & 
Bangsberg, 2004).  Researchers compared the accuracy of patient recall of adherence 
over 1, 3, 7, and 30-day intervals.  Although it was expected that shorter periods of time 
would result in the most accurate recall, researchers found that the 30-day VAS 
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performed slightly better than other measures of self-reported adherence over shorter 
periods of time (Bangsberg, Bronstone, & Hofmann, 2002). 
Self-Report Instruments and Questionnaires 
Several adherence measurement instruments have been reported in the literature 
primarily in the context of clinical research trials.   Most adherence questionnaires ask 
patients to recall the specific number of missed medication doses over a certain time 
period such as the last 2-7 days.  Patients are typically asked to recall day-by-day and 
medication-by-medication doses or missed doses.   Table 2 summaries adherence self-
report instruments. 
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Table 2  
Adherence Measurement Instruments 
 
Instrument Description Population Studied Reliability/Validity 
 
Adult AIDS Clinical Trial 
Group (AACTG) Adherence 
Baseline Questionnaire 
(Chesney et al., 2000) 
9-page self-report of beliefs about 
medications, social support, 
missed or late doses, self-
efficacy, psychological  distress, 
health habits, alcohol and drug 
use, sociodemographic 
characteristics and a 20-item 
symptom index. Takes 
approximately 10 minutes to 
complete. Approximately 62 
items. 
HIV infected patients, 
20% female, 30 non-
white 
No detailed information 
available.  Authors believe the 
instruments “appear to be 
practical, acceptable to patients” 
and investigators and should 
prove useful for efficient 
collection of data describing  
adherence to medications within 
clinical trials populations.” 
 
Highly significant association 
was seen between self-report of 
missed doses and detectable 
viremia.  Several correlates of 
non-adherence were identified. 
Adult AIDS Clinical Trial 
Group (AACTG) Adherence 
Follow Up Questionnaire 
(Chesney et al., 2000) 
6-page self-report of missed or 
late doses, medication doses, 
food requirements or special 
instructions, reasons why doses 
were missed and a 20-item 
symptom index. Approximately 
47 items. 
HIV infected patients, 
20% female, 30 non-
white 
    
Community Programs for 
Clinical Research on AIDS 
(CPCRA) Antiretroviral 
Medication Self-Report (Form 
646) (Mannheimer, Friedland, 
Matts, Child, & Chesney, 
2002) 
7 day global recall of amount of 
each medication taken (all, most, 
about half, very few, none).  
Number of items varies based on 
number of ARV agents. Includs 
checklist of 10 possible reasons 
why ARV doses were missed. 
HIV infected patients, 
20% female, 72% non-
white. 
Not reported. 
    
Godin’s Self-Reported 
Questionnaire Assessing 
Adherence to Antiretroviral 
Mediation (Godin, Gagne, & 
Naccache, 2003) 
9 main questions of which 3 
address nonadherence.  
Developed in French and 
English. 
Predominantly HIV 
infected men who have 
sex with men 
Not reported, although authors 
stated, “adequate psychometric 
properties” (Godin et al, 2003, 
page 329) 
    
Morisky Medication 
Adherence  Scale (MMAS)   
(Corless et al., 2005; Morisky, 
Green, & Levine, 1986) 
4 brief yes or no questions that 
address barriers to medication-
taking and permit the clinician to 
reinforce positive adherence 
behaviors 
Limited use in HIV 
disease; primarily 
studied in patients with 
hypertension, asthma 
and hyperlipidemia 
Internal consistency, α = 0.61 - 
0.65  
    
Patient Medication Adherence 
Questionnaire Version 1.0 
(PMAQ-V1.0) (DeMasi et al., 
2001) 
6 items assess medication-taking 
behaviors; 25 items assess 
barriers and motivators to taking 
medication 
HIV infected patients, 
85% male, 32% non-
white. 
Internal consistency, α = 0.79 
    
Pictographic Medication Self-
Efficacy Scale (Kalichman et 
al., 2005) 
Pictographic and color visual 
analogue scale for assessing self-
efficacy for medication 
adherence. Uses 6 scenarios. 
HIV infected patients, 
36% women, 99% 
African-American 
Internally consistent (α = 0.68); 
stability (2-week test/retest r = 
0.63); evidence for convergent 
and divergent construct validity. 
    
Simplified Medication 
Adherence Questionnaire 
(SMAQ) (Knobel et al., 2002) 
6 items based on Morisky scale HIV infected patients, 
72% male, 65% IDU 
 
72% sensitivity; 91% specificity; 
likelihood ratio of 7.94 to 
identify nonadherent patients, 
compared with MEMS; Internal 
consistency, α = 0.75; Inter-
observer agreement 88.2%, 
kappa 0.74. 
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The Adult AIDS Clinical Trial Group (AACTG) developed both a baseline and a 
follow-up self-report adherence assessment instrument for use in clinical trials.  These 
instruments have been included in a number of AACTG clinical trials to date and have 
been widely disseminated to investigators both in the United States and abroad (Chesney 
et al., 2000).  The Community Programs for Clinical Research on AIDS (CPCRA) 7-day 
global recall adherence questionnaire produced adherence data that predicted biologic 
outcomes including HIV RNA and CD4 lymphocyte count.  Adherence was associated 
with non-detectable HIV RNA levels, a change in HIV RNA levels and a change in CD4 
lymphocyte counts over a 12 month period (Mannheimer, Friedland, Matts, Child, & 
Chesney, 2002).   
Morisky, Green and Levine (1986) developed an instrument to assess adherence 
to hypertension therapy which also addresses barriers to medication-taking.  This tool has 
been incorporated into several studies involving HIV-infected patients and demonstrated 
success within this population (Corless et al., 2005; Gao & Nau, 2000).  Knobel et al. 
(2002) developed the Simplified Medication Adherence Questionnaire (SMAQ) to 
identify non-adherent patients and determined the instrument to be adequate in most 
clinical settings.  The Patient Medication Adherence Questionnaire (PMAQ) assesses 
medication-taking behaviors and barriers to adherence with HAART. Self-reported 
adherence derived from this instrument predicted virologic outcomes but the authors 
suggested additional refinement of the dimensions is needed (Boyle, 2003; DeMasi et al., 
2001). 
Some researchers have either developed their own assessment tools or have 
modified versions of other instruments, thus complicating the ability to compare data 
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from different studies.  Gau and Nau (2000) measured adherence using a Morisky-type 
scale and two other measures of self-reported adherence to evaluate accordance yet found 
discordant results.  They recommend caution when comparing adherence rates between 
studies that use different methods for assessing adherence. 
Using self-report, Hill et al. (2003) studied patients’ definitions of adherence, 
beliefs about consequences of nonadherence and reasons for current and past adherence 
behavior.  They identified three categories of adherence: 1) consistent adherers; 2) 
currently adhering but with prior nonadherence; and 3) currently not adhering. They also 
identified nine patterns of adherence: 1) takes medication very rarely; 2) alternates 
between long period of taking and not taking medication; 3) skips entire days; 4) skips 
doses; 5) skips one type of medication; 6) takes medication late; 7) does not stick to food 
requirements or restrictions; 8) adheres to a purposely modified regimen and 9) adheres 
to an unknowingly incorrect regimen.  Noting that patients have definitions of adherence 
that may be quite different from the definitions used by clinicians, they suggested that 
adherence questionnaires and assessment tools need to reflect the diversity of patient 
beliefs and patterns of medication-taking to more accurately measure adherence or less 
than optimal adherence. 
In a large meta-analysis Simoni and colleagues (2006) observed a robust pattern 
of association between self-reported adherence and HIV RNA.  In 84% of recall periods, 
self-reported adherence was associated with HIV RNA based on odds ratios or simple 
measures of correlation.  The association was statistically significant across a variety of 
self-reported measures, administration modalities, and recall periods.  These findings are 
consistent with the conclusions of a meta-analysis of adherence studies performed by 
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Nieukerk and Oort (2005).  The association between self-report and CD4 cell count was 
less consistent, a finding that was not entirely unexpected since HIV RNA and CD4 
count generally correlate, but discordant results are common.  They concluded that even 
brief self-report measures of HAART adherence can be robust.  
Clinician Assessment 
Studies examining healthcare provider abilities to predict their patients’ adherence 
have been inaccurate and overly optimistic leading to the misidentification of 
nonadherent patients (Bangsberg, Hecht et al., 2001; Haubrich et al., 1999).  Paterson 
(2000) found that physicians predicted adherence incorrectly for 41% of patients 
compared with nurses who predicted it incorrectly for 30% of patients. 
Miller and colleagues (2002) found that clinicians overestimated medication 
adherence by almost 9% and inadequately detected poor adherence.  Consequently, 
clinicians missed opportunities to intervene with appropriate adherence interventions.  
Miller and Hays (2000b) suggested that clinicians’ subjective assessment of adherence 
may be as problematic as a patient’s self-reported adherence.  HIV care providers in 
routine clinical practice rarely predicted patient adherence. This often means that when 
health care providers do not use patient reports of adherence, they are leaving the most 
critical determinant of HIV treatment outcome to chance (Bangsberg, 2006). 
Objective Measures of Adherence 
 In contrast to subjective measures, objective measures rely on data recorded 
independently of the patient (Orrell, 2005).  The following objective measurement 
methods will each be reviewed:  directly observed therapy, therapeutic drug monitoring, 
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biomedical examination, pill counts, electronic monitoring devices, and pharmacy refill 
data. 
Directly Observed Therapy 
One way of assessing adherence is participation in directly observed therapy 
(DOT) in which administration of each dose is directly monitored.  DOT has been used in 
the treatment of tuberculosis for decades and was later applied to HIV treatment (Mitty, 
Stone, Sands, Macalino, & Flanigan, 2002). The first randomized controlled trial of 
community-based DOT in HIV care revealed significantly higher levels of self-reported 
adherence, higher CD4 lymphocyte response, and greater HIV RNA reduction than those 
not participating in DOT (Altice, Mezger, & Bruce, 2003).  DOT programs, often 
modeled after those used in tuberculosis treatment programs, may not be practical in HIV 
care due to the large and growing numbers of HIV-infected patients since these programs 
are labor intensive, expensive and can be perceived as intrusive (Liechty & Bangsberg, 
2003).   While DOT may be more feasible with the increasing number of once a day 
HAART regimens, many of these daily regimens are administered at bedtime which 
increases the impracticality of DOT for this group of patients. 
Therapeutic Drug Monitoring (TDM) 
Monitoring of plasma and urinary drug levels has been proposed in clinical and 
research settings.  Serum levels of some drug metabolites provide evidence that 
individuals are taking medication but they do not provide specific information about the 
number of doses missed or taken, individual patterns of missed doses, or adherence to a 
medication based on a time schedule.  This method is prone to wide individual variation 
in drug pharmacokinetics related to the properties of drugs, drug-drug interactions and 
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variations in drug absorption. Moreover, drug levels may only reflect recently taken 
medication doses rather than long-term patterns of drug levels (Miller & Hays, 2000a).  
Low drug levels have been associated with self-reported nonadherence and virologic 
failure (Murri et al., 2000; Nieuwkerk et al., 2001). TDM also is limited by a lack of 
technologic standardization of assays as well as limited general availability of the 
laboratory assays (Acosta & Gerber, 2002).   
Some researchers have attempted to exploit the biologic changes induced by 
antiretroviral agents to indirectly measure adherence.  Stavudine and zidovudine can raise 
the mean corpuscular volume, didanosine can alter uric acid levels and both indinavir and 
atazanavir can increase bilirubin levels.  While these data provide some degree of 
objective measurement, they are only marginally sensitive and specific markers of 
medication adherence and provide little information about individual patterns of missed 
doses (Cinti, 2000; Miller & Hays, 2000a). 
Biomedical Examination 
Laboratory measurement of CD4 lymphocytes and HIV RNA levels has been 
used as indirect measures of adherence.  Wood and his colleagues (2004) determined that 
adherence was the strongest independent predictor of an increase in CD4 lymphocyte 
count after beginning HAART therapy.  Unfortunately, biomedical markers including 
CD4 lymphocyte cell counts and HIV RNA levels do not always correlate with adherence 
levels.  Patients can have a drug-sensitive virus and be adherent to their HAART regimen 
yet still experience HAART failure due to the development of drug-resistant HIV strains, 
drug interactions and unfavorable pharmacokinetic properties (Miller & Chang, 2002).   
Additionally, laboratory testing can be expensive.  Laboratory measures may be 
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considered more useful when used in combination with other adherence measures such as 
pill counts, self-report assessments and EDM (Cinti, 2000).  
Pill Counts 
Pill counts frequently are used in conjunction with clinical drug trials and provide 
an objective means of assessing the number of pills removed from the bottles.   Pill 
counts are easy and inexpensive to perform (Miller & Hays, 2000b). Disadvantages of 
pill counts are that they can be time consuming for clinical and research staff; they do not 
guarantee that the pills were taken as prescribed; patients may knowingly empty the 
bottle prior to the visit in anticipation of a pill count; they may forget to bring bottles to 
the clinical site; and some may perceive pill counts as intrusive (Berg & Arnsten, 2006).  
Unannounced pill counts may provide a more accurate assessment of adherence 
rates than self-report.  In one study this method was more predictive of HIV RNA than 
self-reported adherence measures and performed well compared to electronic data 
monitoring using computerized medication caps (Bangsberg et al., 2000).  Unannounced 
pill counts may not be practical in many settings since home visits are usually required. 
Electronic Monitoring Devices  
Computer-assisted electronic drug monitoring devices, also commonly referred to 
as electronic data (and sometimes drug) monitoring (EDM) devices, are frequently used 
in research settings and to a lesser extent clinical settings.  Small electronic chips 
embedded in the caps of pill bottles record each time a bottle is opened or closed and the 
length of time the bottle is open.  Data is downloaded to a personal computer periodically 
for analysis. One of the more common EDM products is the Medication Event 
Monitoring System (MEMS) (New York State Department of Health, 2001). 
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Data collected from EDM equipment has been found to correlate highly with 
concurrent HIV RNA (Samet, Sullivan, Traphagen, & Ickovics, 2001).  Limitations 
related to EDM include expense and the possibility of under-reporting adherence in 
patients who elect to remove more than one dose at a time. Under-reporting may occur 
when patients remove medication to fill a pill box or remove extra doses in planning to be 
away from home for an extended period of time.  EDM also assumes that the patient 
actually takes each removed pill.  Over-reporting can also occur as pills may be removed 
but not swallowed and bottles may be opened without removing pills. EDM methods 
have additional drawbacks including inconvenience, patient dissatisfaction and 
confidentiality concerns (Mannheimer, Friedland, Matts, Child, & Chesney, 2002).  EDM 
is rarely used in clinical practice due to the expense of the equipment. 
Pharmacy Refill Monitoring 
Pharmacy refill data can serve as an adherence measure by providing the dates on 
which antiretroviral medications were dispensed.  This measure is based on a 
straightforward premise that when a patient does not receive timely refills of a drug from 
the pharmacy, he or she is either not taking medication between refills or is missing doses 
such that a given prescription lasts longer than it should (Turner, 2002). Researchers have 
studied the number of prescriptions picked up, timeliness of medication pickup and gaps 
in medication based on refill data.  These measures are usually calculated based on the 
number of days’ supply obtained divided by the total number of days in the period or the 
number of refills obtained divided by the expected number of refills over a given time 
period (Steiner & Prochazka, 1997).  Low-Beer, Yip, O’Shaughnessy, Hogg and 
Montaner (2000) examined pharmacy dispensing data and found a significant linear trend 
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in viral suppression across ordered categories of adherence.  Pharmacy refill adherence 
rates of 95% or greater were associated with high virologic success; success rates 
decreased sharply with decreasing levels of adherence to refills.   
Several studies have used pharmacy data to assess adherence among patients with 
HIV disease. One study found that self-reported HAART adherence correlated with 
pharmacy dispensing records and predicted viral suppression at levels > 97% (Fairley, 
Permana, & Read, 2005).  Grossberg and colleagues (2004) demonstrated that adherence, 
as measured by time-to-pharmacy refill, was able to distinguish an HIV RNA impact 
among individuals self-reporting perfect adherence.  Patients who were adherent to 
HAART as measured by consistent pharmacy refills for greater than 4 months were 
significantly more likely to achieve virologic control and immunologic benefit than were 
less-adherent patients (Maher et al., 1999).   Using pharmacy-based adherence measures, 
Kitahata et al. (2004)  determined that higher levels of adherence to HAART were 
significantly associated with longer time to virologic failure, greater increase in CD4 
lymphotcyte count, and lower risk of progression to clinical AIDS or death.  After 
controlling for other factors, patients with low adherence had over five times the risk of 
disease progression in patients with moderate adherence, or patients with high adherence. 
Assessing refill records is non-intrusive and reduces the possibility of bias in the 
research process as subjects are usually not aware that their behavior is being monitored. 
However, like other measures of adherence, pharmacy refill pickup does not assure that 
the patient actually took the medication as prescribed (Miller & Hays, 2000b).  
Combined Methods of Adherence Measurement 
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To address the limitations of any one measurement approach, some researchers 
have suggested that adherence measurement methods be combined (Kerr, Walsh, Lloyd-
Smith, & Wood, 2005).  The use of medication diaries with computer-assisted self-
interviewing gave insight into patients’ adherence patterns (Hugen et al., 2002).  Self-
reported adherence data has also been shown to enhance data obtained from electronic 
monitoring methods (Bangsberg et al., 2000).   
Liu and colleagues (2001) examined different adherence measures applied to the 
same patient and found that different methods of measurement suggested different levels 
of adherence. Adherence was underestimated by EDM and overestimated by pill count 
and interview.   Data obtained from EDM, pill counts, and interviews were subsequently 
merged into a composite adherence score (CAS).  While adherence as measured by CAS, 
EDM, pill count, and interview were associated with achievement of undetectable 
viremia within six months of initiating HAART therapy, the CAS demonstrated the 
strongest predictive relationship.  Although the summary measure combining several 
measures was more strongly related to a clinical response, they suggested a more 
practical measurement method is needed for clinical use.   
Berg and Arnsten (2006) suggested that adherence is especially difficult to 
measure because it is composed of several distinct behaviors.  Component adherence 
behaviors include obtaining refills, ingesting the right number of pills, ingesting pills 
within an effective dosing interval, and ingesting pills in accordance with any appropriate 
dietary requirements.  Individual measures of adherence frequently measure just one 
single aspect of adherence behavior.  This phenomenon of  “construct under-
representation” occurs when a measure fails to assess important dimensions of the 
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construct in question (Hubley & Zumbo, 1996).  Although some adherence measures 
such as EDM provide the ability to measure several aspects of adherence, the data are not 
generally analyzed in this manner.  EDM and other measures are vulnerable to another 
validity threat caused by measuring unrelated constructs.  The term “construct irrelevant 
variance” is used when a measure contains excess variance attributable to unrelated 
constructs (Berg & Arnsten, 2006).  
No single method has been established as the gold standard for measuring 
adherence.  Each method has advantages as well as disadvantages.  The HIV treatment 
guidelines published by the HIV Medicine Association of the Infectious Diseases Society 
of America suggested that once an adherence assessment method has been selected, it 
should be used consistently to monitor each patients’ adherence at each visit (Aberg et 
al., 2004).  Chesney (2006) indicated that it is unlikely that a single optimal measurement 
of adherence can be found as the reasons for measuring adherence vary based on whether 
the assessment is for research or clinical purposes and require further refinement based 
on the research questions being investigated or the clinical needs being addressed.  
Consequently, it is unlikely that a single optimal intervention can be developed because 
the reasons for nonadherence are as diverse as the populations affected by HIV disease. 
In summary, there is no clear and universal method to rigorously measure 
individual patients’ adherence.  Rigorous adherence measurement requires 
interdisciplinary collaboration between social scientists and HIV researchers.  Improving 
the measurement of HAART adherence would facilitate the development and evaluation 
of adherence-improving interventions with standardized and empirically tested adherence 
measures (Berg & Arnsten, 2006). 
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Measurement of Treatment Outcomes 
 The success as well as failure of HIV treatment can be evaluated using virologic, 
immunologic, and clinical criteria.  Virologic indicators appear earliest after initiating 
HAART and are represented by a decrease (in the case of success) or increase (in the case 
of failure) in HIV RNA.  Immunologic treatment success or failure usually occurs next 
and is measured by an increase (success) or decrease (failure) in the CD4 lymphocyte 
count.  Although clinical treatment failure, if it occurs, usually becomes apparent much 
later, clinical success can often be assessed early after the initiation of HAART as many 
patients experience an improvement in HIV-related constitutional symptoms, such as 
weight loss, generalized lymphadenopathy, fever, and night sweats (Hoffman, Rockstroh, 
& Kamps, 2006).  
Measurement of Virologic Outcomes 
Virologic success is defined as a reduction of HIV RNA to below the level of 
detection. This is based on an understanding that the more rapid and greater the decrease 
in HIV RNA, the longer the therapeutic effect (Kempf et al., 1998; Powderly et al., 
1999).  Commercially available assays which measure HIV RNA vary based on the lower 
level of detection and dynamic ranges.  The most common lower-level thresholds report 
HIV RNA levels as less than (<) 50 copies, < 75 copies and < 80 copies based on the 
testing methodology and equipment being used. While a lower level threshold of  <50 
HIV RNA copies is most common, there are no data suggesting less virologic success 
when HIV RNA is measured with alternative thresholds (Hoffman, Rockstroh, & Kamps, 
2006).  Table 3 describes the common HIV RNA testing methodologies. 
 
   
 
 
 
41
Table 3 
 
Quantitative Plasma HIV RNA Techniques 
 
    
Technique Test Name Manufacturer Dynamic Range 
HIV RNA PCR  
(RT-PCR) 
Amplicor HIV-1 Monitor 
Test version 1.5 
Roche < 50  – 750,000 
copies/ml 
 
Branched chain DNA 
(bDNA) 
Versant HIV-1 RNA 3.0 Bayer < 75 – 500,000 
copies/ml 
 
Nucleic acid sequence-based 
amplification (NASBA) 
NASBA or NucliSens 
HIV-1 QT 
bioMerieux <80 – 3,500,000 
copies/ml 
 
Adapted from Bartlett & Gallant (2005)  
 
HIV RNA is the most commonly used variable used by clinicians to assess patient 
measures of adherence but it is also affected by antiretroviral drug resistance and drug 
bioavailability (Wagner et al., 2001).  Serial measurements of HIV RNA are routinely 
used to monitor the effectiveness or failure of therapy and help to determine if the 
beneficial effect of treatment is being maintained or lost.  A change of  > 3-fold or > 0.5 
log10 copies/ml is considered significant (Bartlett & Gallant, 2005; Steinhart, Orrick, & 
Simpson, 2002).   
Measurement of Immunologic Outcomes 
Immunologic treatment success is broadly defined as an increase in the CD4 
lymphocyte count.  It is difficult to individually predict the immunological success of 
therapy for patients on HAART as it varies significantly from one person to another. 
Although individual research studies may have precise operational definitions of 
immunologic success, no standard definition exists (Hoffman, Rockstroh, & Kamps, 
2006).   Immunological treatment success is not always associated with maximal viral 
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suppression as even partial suppression can result in a significant CD4 lymphocyte 
response (Ledergerber et al., 2004).   
Serial measurements of CD4 lymphocytes are routinely used to monitor the 
immunologic response to therapy.   In the absence of HAART, the average rate of CD4 
lymphocyte decline is 4% per year for each log10 HIV RNA copies/ml.   There is a great 
variability in CD4 lymphocyte test results.  For example, the 95% confidence range for a 
true count of 200 CD4 lymphocyte cells per millimeter3  is 118-337 cells per mm3 
(Bartlett & Gallant, 2005).  Several factors can influence the variability of CD4 
lymphocyte counts including laboratory analytical variation and seasonal and diurnal 
fluctuations.  CD4 lymphocyte counts are also used to stage HIV disease and guide 
prophylactic treatment.  A CD4 lymphocyte count <200 copies/mm3 indicates severe 
immunodepression and is a diagnostic marker of AIDS (Bartlett & Gallant, 2005; 
Steinhart, Orrick, & Simpson, 2002). 
Measurement of Clinical Treatment Outcomes 
 Clinical treatment success is dependent on virologic and immunologic success 
and has been reported in numerous studies (Ledergerber et al., 2004; Salzberger et al., 
1999).  Clinical response is not always easy to assess as there is no way to show what 
might have occurred if treatment had not been initiated.  Clinical success is usually 
evaluated based on either the absence of clinical endpoints such as AIDS-defining 
illnesses or death or an improvement in, or resolution of, HIV-related constitutional 
symptoms such as weight loss, generalized lymphadenopathy, fever, and night sweats 
(Bartlett & Gallant, 2005; Hoffman, Rockstroh, & Kamps, 2006).   
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Impact of Medication Adherence on Immunologic and Virologic Outcomes 
 Adherence to HAART has been shown to be an important predictor of virologic 
suppression and of clinical outcomes (Gross, Bilker, Friedman, & Strom, 2001; McNabb 
et al., 2001; Paterson et al., 2000).  HAART adherence is the second strongest predictor 
of progression to AIDS and death, after CD4 lymphocyte count (Bangsberg, Perry et al., 
2001; Garcia de Olalla et al., 2002; Hogg et al., 2002). In a meta-analysis of randomized 
controlled trials (RCTs ) of interventions for adherence to HAART, Simoni and 
colleagues (2006) found that across 19 RCTs with more than 1800 participants, those 
who received an adherence intervention were 1.5 times as likely to report 95% adherence 
and 1.25 times as likely to achieve undetectable HIV RNA levels as participants in 
comparison conditions.    
CD4 lymphocyte response can be somewhat delayed following initial HAART 
initiation.  For this reason, many experts believe that HIV RNA is the best measure of 
therapeutic response to HAART (Nieuwkerk & Oort, 2005).  Bartlett and Gallant (2005) 
believe that the CD4 lymphocyte response is the best clinical prognostic indicator. 
Adherence Interventions: Review of Studies 
Introduction 
Increasing recognition that medication adherence is a determinant of treatment 
outcomes has generated a number of studies investigating methods to support and 
improve adherence. While early research studies on this topic were primarily based on 
small pilot and feasibility studies and had minimal empiric validity, there has been an 
increase in the number of RCTs with adequate sample sizes emerging over the last few 
years (Simoni, Pearson, Pantalone, Marks, & Crepaz, 2006).  In general, patients who 
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receive interventions for adherence are more likely to achieve higher levels of adherence 
and are more often able to achieve undetectable HIV RNA levels than participants in 
various controlled conditions (Chesney, 2006).  Adherence interventions are cost-
effective, and are likely to provide long-term survival benefit to patients (Freedberg et al., 
2006). 
This section will review and summarize studies related to HAART adherence 
interventions.  Interventions will be categorized as 1) patient education and counseling 
strategies; 2) directly observed therapy; and 3) adherence devices and reminders.   
Studies are often characterized as: 1) cognitive (designed to teach, clarify, or instruct); 2) 
behavioral, such as those designed to shape, reinforce, or influence behavior; or 3) 
affective, such as those designed to optimize social and emotional support. 
Patient Education and Counseling Interventions 
The majority of adherence interventions reported in the literature involve 
dedicated time with patients to plan for and support medication adherence.  The 
frequency and nature of these interventions varied, but those that appeared effective were 
characterized by an initial education session followed by ongoing sessions maintained 
regularly over the course of treatment (Machtinger & Bangsberg, 2006).  These studies 
typically involved cognitive interventions or educational interventions targeting patient 
knowledge of drug therapy and employed methods such as counseling by a nurse 
educator, clinical pharmacist, or physician.  Cognitive interventions typically provided 
general information such as dosing instructions, medication description, drug interaction 
information or general information about HAART options. 
   
 
 
 
45
 A wide range of behavioral strategies have been implemented including the use of 
pillboxes, using a register to record administered medications, role-playing medication 
schedules and schedule adjustments, using behavioral problem-solving groups, teaching 
self-monitoring skills, and identifying risk factors for nonadherence.  Some studies used a 
combination of interventions including cognitive and behavioral methods such as 
describing dosing instructions and graphs of HIV RNA levels or educational sessions 
with an adherence counselor and a weekly pill container.  Some studies contained three 
interventions including cognitive, behavioral, and affective techniques. 
 Several published studies have tested educational interventions involving 
healthcare professionals teaching patients about their medications, the importance of 
adherence, and methods to strengthen adherence.  While several researchers found that 
educational interventions had a sustained impact on adherence (Goujard et al., 2003), 
others found minimal or no effect (Rawlings et al., 2003; Remien et al., 2005).   
Virologic and immunologic impact was inconsistently observed.  Adherence 
measurement methods also varied among these studies with EDM and self-report being 
most common.  One researcher utilized cue-dosing (timing doses around meal times or 
regular daily activities) and monetary reinforcement to remind patients to take their 
medications and observed an improvement in adherence that was not sustained and 
returned to baseline with discontinuance of the intervention (Rigsby et al., 2000). 
Two studies examined the effect of pharmacist-led adherence sessions (Haddad et 
al., 2000).  Although patients who received the intervention self-reported higher levels of 
adherence, virologic improvements were only seen in one study (Rathbun, Farmer, 
Stephens, & Lockhart, 2005).  Knobel (1999) administered individual advice regarding 
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adherence and the effect was measured with structured interview and pill counts.  Those 
who received individual counseling had significantly better adherence rates than those 
who did not, but there was no significant difference in virologic response.  
Several studies have tested motivational interviewing and cognitive-behavioral 
problem-solving approaches to improve adherence.  Adherence was consistently higher 
in patients who received these interventions.  While Safren et al. (2001) found little 
difference between patients that received a single intervention session compared with 
patients who simply maintained a pill diary and completed an adherence questionnaire, 
patients who received motivational interviewing led by nurses reported higher medication 
adherence than those receiving usual care and were more likely to follow the medication 
regimen as prescribed by their health care provider (DiIorio et al., 2003).   
In another study, patients received 10 sessions of cognitive-behavioral stress 
management and expressive supportive therapy (Jones et al., 2003).  Participants were 
assessed on self-reported medication adherence over seven days along with coping 
strategies and beliefs related to HAART. Patients with low baseline adherence that 
received the intervention significantly increased their mean self-reported adherence by 
approximately 30%.  Those in the usual care group showed a non-significant increase in 
adherence.  After receiving monthly cognitive behavior therapy sessions over a one year 
period, Weber (2004) found that patients’ mean adherence as measured by EDM was 
similar between the intervention and standard care group.  While the proportion of 
patients with adherence levels > 95% was significantly higher in the intervention group, 
virologic outcomes in both groups were similar. 
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Smith, Rublein, Marcu, Brock and Chesney (2003) examined the effect of a self-
management intervention based on feedback of adherence performance and principles of 
social cognitive theory on adherence.  Individuals in the self-management group were 
significantly more likely to take 80% or more of their doses each week than individuals 
in the control group as measured by EDM. 
In summary, some improvement in adherence has been seen with education and 
counseling-based interventions but the results were inconsistent and frequently 
diminished when the intervention was terminated.  Significant immunologic and 
virological improvements were inconsistently observed. 
Directly Observed Therapy 
Directly observed therapy (DOT) has been studied as an adherence intervention 
based on its successful use in treating nonadherent tuberculosis patients.  Fischl (2001) 
and her team compared patients receiving DOT in a correctional facility to those 
receiving standard outpatient clinic services and found that patients who received DOT 
had a significantly higher chance of achieving undetectable HIV RNA than those that 
received standard clinic care.   
Altice, Mezger and Bruce (2003) compared DOT for once- daily dosing, modified 
DOT (twice-daily dosing in which one dose was give via DOT) and standard care.  The 
patients receiving DOT had significant improvements in three-day self-reported 
adherence, six-month median CD4 lymphocyte response, and six months median 
reduction of HIV RNA.  In another study, pregnant women who were identified as being 
at very high risk for HAART nonadherence and consequent mother-to-child transmission 
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were given DOT during the third trimester of pregnancy.  Clinical outcomes of no 
perinatal transmission of HIV, suppression of HIV RNA, and receipt of appropriate 
antiretroviral agents during labor were similar to those that received standard care 
(Bryant, Collingham, & Till, 2004). 
While studies of DOT have resulted in improvements in clinical outcomes 
associated with HAART, DOT programs may not be appropriate for most clinical setting 
as they are expensive, labor-intensive and frequently perceived by patients as intrusive 
(Liechty & Bangsberg, 2003).  Machtinger and Bangsberg (2007) believe that the best 
candidates for DOT are those with low motivational states who have experienced failure 
with less intensive adherence support and who have advanced HIV disease. 
Adherence Devices and Reminders 
A number of devices are available to help patients adhere to their medication 
regimen including medication organizers such as pillboxes, reminder devices such as 
alarm watches and pagers, and visual medication schedules.  Golin and her team (2002) 
found that patients who used more adherence aids were more adherent. The 
manufacturers of electronic drug monitoring devices have even added clocks and alarms 
to their equipment to help remind patients to take their medication as prescribed (Miller 
& Hays, 2000a).  Most devices are simple, inexpensive, and easy to integrate into the 
routine care of patients. Pill boxes allow patients to organize their doses of medication in 
a convenient location. They eliminate the need to carry multiple medication bottles and 
provide a means to verify whether doses have been taken.   Clinicians can monitor for 
nonadherence if patients take pillboxes to clinical appointments.  Some pharmacies 
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provide medications prefilled into weekly or monthly organizers (Machtinger & 
Bangsberg, 2006; Machtinger & Bangsberg, 2007).   
While the success of these devices has primarily been reported based on clinical 
and field experience, several research studies have been conducted related to this area.  
McPherson-Baker et al. (2000) prospectively studied patients who participated in weekly 
sessions using pillboxes combined with monthly individualized adherence counseling.  
After five months, those receiving the intervention had a significant improvement in their 
adherence as measured by pharmacy refill data and fewer hospitalizations. 
Because many patients cite ‘forgetting’ as a primary reason for missing doses of 
HAART, reminder devices such as alarms on watches, pagers and other electronic 
technology are recommended to provide multiple daily reminders (Chesney, 2000; 
Chesney, Morin, & Sherr, 2000).  Andrade et al. (2005) measured the effect of a 
memory-prompting device combined with monthly adherence counseling on adherence to 
HAART in memory-intact and memory-impaired subjects in a prospective RCT.  Mean 
adherence scores as measured by EDM did not differ between the intervention and 
control group.  However, a subset of memory-impaired patients who received the 
intervention had significantly higher levels of adherence.  
  Safren and his team (2003) tested a customizable reminder system using web-
based pager technology to increase and maintain adherence in patients with pre-existing 
adherence problems. After a two-week monitoring period with EDM, participants with 
less than 90% adherence were randomized to continue monitoring or to receive a pager. 
Compared to standard care, the group who received the pagers had greater improvements 
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in adherence through the first three months but adherence at the end of the study was still 
poor in both groups. Safren suggested that more intensive interventions are required for 
patients with pre-existing problems.  
 Visual medication schedules contain pictorial displays of HAART agents 
superimposed on calendars as visual reminders of which pills to take and at what times.  
Although not tested in patients receiving HAART, Schillinger (2003) found that these 
visual schedules improved outcomes in patients receiving anticoagulation therapy 
(another chronic disease state involving daily medication that requires high levels of 
adherence). 
Qualitative Reviews and Meta-Analyses of HAART Interventions 
The literature related to HAART adherence interventions has been reviewed 
several times.   Early qualitative reviews indicated that reports were based primarily on 
small pilot and feasibility studies and offered few prescriptive guidelines with minimal 
empiric validity. While later reviews highlighted the improved rigor of the studies, 
considerable variation in sampling and assessment strategies, intervention components, 
and findings was noted (Simoni, Pearson, Pantalone, Marks, & Crepaz, 2006).  
Fogarty et al. (2002) published the first comprehensive literature review all of 
published articles reporting interventions designed to increase adherence to HAART.  
Although 16 interventions were identified employing a wide range of behavioral, 
cognitive and affective strategies, only 11 included data on intervention and efficacy and 
the effects of these interventions were generally weak.    
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Simoni, Pantalone, Frick and Turner (2005) performed a meta-analysis of 15 
randomized controlled trials related to adherence interventions and found some 
significant differences in either adherence or clinical impact between the intervention and 
control arms in 10 of the studies.  They noted several significant concerns: 1) the findings 
were difficult to interpret due to the heterogeneity in the studies; 2) the duration of 
treatment intervention varied from 1 to 10 sessions with ongoing follow-up ranging 
anywhere from 1 day to more than 1 year; 3) the methods used to assess adherence varied 
from different types of self-report to EDM; and 4) measurement of immunologic and 
virologic response was uncommon. Improvement in adherence was not commonly 
sustained.  Unfortunately, findings from similar interventions were inconsistent.  For 
example, in two studies, cognitive-behavioral treatment was part of a successful strategy 
(Safren et al., 2001; Weber et al., 2004) but in two others it was not (Jones et al., 2003; 
Murphy, Lu, Martin, Hoffman, & Marelich, 2002).  Simoni's (2005) review of the 
literature suggested a lack of empirical data necessary to make strong recommendations 
regarding the most efficacious way to improve adherence to HAART.  
Simoni and her team (2006) conducted another meta-analysis to determine 
whether behavioral interventions addressing HAART adherence were successful in 
increasing the likelihood of a patients attaining 95% adherence or undetectable HIV 
RNA. Nineteen studies with a total of 1839 participants met their selection criteria of 
describing a randomized controlled trial among adults that evaluated a behavioral 
intervention with HAART adherence or HIV RNA as an outcome. Random-effects 
models indicated that across studies, those who received an adherence intervention were 
1.5 times more likely to report 95% adherence and 1.25 times more likely to achieve an 
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undetectable HIV RNA compared to participants who did not receive an intervention. 
The intervention effect for 95% adherence was significantly stronger in studies that used 
recall periods of 2 weeks or 1 month as compared to 7 days or less. They concluded that 
more research is needed to identify the most efficacious intervention components and the 
best methods for using them in actual clinical settings (Simoni, Pearson, Pantalone, 
Marks, & Crepaz, 2006).   
Amico, Harman and Johnson (2006) performed a research synthesis of HAART 
intervention outcome studies published between 1996 and 2004. Effect sizes were 
calculated for each study outcome resulting in 25 immediate post-intervention outcomes 
and an additional 13 follow-up effect sizes.  They found small effect size (d = 0.35, odds 
ratio [OR] = 1.88) that varied considerably across studies.  Interventions that specifically 
enrolled participants with known or anticipated problems with HAART adherence 
demonstrated medium effects on adherence (d = 0.62, OR = 3.07). Interventions that did 
not target their participants on similar criteria had small effects (d = 0.19, OR = 1.41). 
Adherence improvements showed no tendency to decay with time.  The authors 
concluded that adherence intervention outcome studies must carefully delineate their 
target populations because defining individuals as "on HAART" does not provide the 
level of specificity needed to design and implement effective adherence interventions. 
Given the relatively small effects observed from studies of single adherence 
interventions and in an effort to expand the breadth of adherence issues addressed by 
these interventions, combinations of adherence interventions are suggested by many 
adherence experts.  Studies of patients with other chronic diseases suggest that 
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approaches addressing only one factor related to adherence will not be as powerful as 
interventions addressing multiple factors (Miller & Hays, 2000a).   
Despite the need for programs and procedures that support or enhance adherence 
to HAART, little evidence exists about the extent to which clinical practices have been 
able to incorporate adherence interventions into their routine care.  Investigators 
conducted a survey of clinical care settings in New York and Connecticut and determined 
that the current standard of care is to provide only minimal levels of adherence services. 
They also found that ad hoc adherence support was frequently offered on an as-needed 
basis (Harman, Amico, & Johnson, 2005).  These findings support the need for the 
ongoing development of adherence interventions that are easily translatable to real-life 
clinical practice.  
In some cases an intervention can become the standard of care despite the empiric 
data demonstrating its efficacy.  In these cases it may be considered unethical to assign 
patients to the control arm of a trial.  For example, randomized controlled trials have 
provided evidence that behavioral interventions improve adherence to HAART.  Such 
interventions are increasingly considered the standard of care, making additional 
randomized trials less likely (Petersen, Wang, van der Laan, & Bangsberg, 2006).   
In the absence of conclusive empirical data, clinicians have frequently turned to 
adherence strategies recommended by experts which are based on limited data, research 
from adherence in other disciplines, clinical practice experience and demonstrated 
correlates of adherence (Simoni, Pantalone, Frick, & Turner, 2005).  For example, the 
Best Practices Guide, published online by the American Public Health Association (Jani, 
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2002) proposes a practical four step approach in the management of adherence: 1)  assess 
factors that may influence adherence and function as potential barriers; 2) develop and 
maintain a therapeutic alliance with the patient; 3) monitor the level of adherence using 
multiple measures; and 4) implement multiple targeted interventions to resolve barriers to 
adherence.  Chesney (2003), Turner (2002) and the American Psychological Association 
(1997) offered similar adherence management guidelines and recommendations which 
are summarized in Table 4. 
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Table 4 
Adherence Management Guidelines and Recommendations 
Turner APA Chesney 
Simplify and explain the 
treatment regimen. 
Clarify the regimen. Deliver an introductory 
statement. 
Provide reminder 
devices. 
Tailor it to individual lifestyles. Confirm understanding of the 
regimen. 
Discuss potential side 
effects. 
Facilitate interaction with clinic 
staff. 
Assess adherence. 
Provide social support. Identify and remove personal 
barriers to adherence. 
Ask about reasons for 
missing doses. 
Treat concomitant 
psychological disorders 
and substance abuse 
problems. 
Refer patients with special needs 
such as substance abuse to 
appropriate treatment. 
Ask about medication side 
effects or other problems. 
 Enhance self efficacy: offer positive 
feedback for new skills, 
demonstrated problem-solving and 
ways to integrate the regimen into 
their lives. 
 
 Create a social environment 
conducive to adherence: enlist 
support from patient's social 
network and maintain support of the 
clinical team. 
 
Adapted from Turner (2002) Adapted from APA (1997) Adapted from Chesney (2002) 
 
Summary 
Improving adherence to HAART may require a combination of methods 
appropriate to the patient and clinical setting. Alterable factors known to impact 
adherence, such as depression, substance abuse, and the therapeutic relationship between 
patient and provider should be addressed in a proactive and ongoing manner. Adherence 
interventions should include dedicated educational and collaborative time with patients to 
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plan for medication adherence and to maintain necessary support and collaboration 
throughout the course of treatment. In this way, problems such as side effects can be 
addressed, medications simplified or changed if necessary, and adherence devices 
supplied as deemed appropriate.   Most of the adherence intervention strategies studied to 
date have focused on factors directly related to patient behaviors.  Other variables known 
to impact adherence have not been thoroughly studied including factors related to the 
healthcare provider, the patient-provider relationship, factors related to the treatment 
regimen or illness, environment factors and contextual factors (Simoni, Pantalone, Frick, 
& Turner, 2005).    
As successfully tested interventions emerge in the literature, it is critical that the 
information be disseminated into clinical practice. The issue of efficacy versus 
effectiveness will need to be addressed because what works successfully in a research-
based trial may not work in clinics which face challenges such as limited staff and 
resources as well as diverse patient populations (Simoni, Pantalone, Frick, & Turner, 
2005). 
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CHAPTER THREE: METHODS 
Introduction 
This chapter presents the research methods and procedures for this study.  It 
includes treatment conditions, background information related to the structured adherence 
intervention, the study design, description of the study population and setting, inclusion 
and exclusion criteria, data collection procedures, data management, and the data analysis 
plan. 
Treatment Conditions 
Overview of the Study 
This retrospective comparative study compared treatment response, pharmacy 
refill adherence, and self-reported medication adherence between two groups of patients: 
those participating in an AIDS Drug Assistance Program (ADAP) and those participating 
in a Medicaid-funded medication access program.  The ADAP served as a structured 
adherence intervention (SAI) based on procedural and administrative processes required 
by the state-managed program.  Those patients receiving antiretroviral medications as 
part of the Medicaid-funded program were considered usual care as this program did not 
contain systematic procedural and administrative conditions which could impact 
adherence.   A number of other variables can impact medication adherence including 
adherence interventions (adherence counseling, education, and aids), ARV-related 
factors, sociodemographic factors, and HIV disease specific factors.  Figure 1 depicts the 
conceptual model developed to structure this study based on existing research findings. 
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Figure 1.  Conceptual Model for Evaluating the Effects of a Structured Adherence 
 
Intervention to HAART on Adherence and Treatment Response Outcomes. 
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Structured Adherence Intervention 
Introduction: National AIDS Drug Assistance Program 
The AIDS Drug Assistance Program (ADAP) is a federal program administered 
by each state to provide medications for the treatment of HIV disease.  Eligibility to 
participate in the ADAP is based on the lack of adequate health insurance and financial 
resources necessary to cover the cost of medications.  While some clients are enrolled in 
ADAP on a long-term basis, others participate temporarily while they await acceptance 
into other insurance programs. Each state AIDS Drug Assistance Program is unique in 
which medications are included in its formulary and how those medications will be 
distributed (Department of Health and Human Services, 2007).   
Florida AIDS Drug Assistance Program 
The ADAP for the State of Florida is centrally administered by the Bureau of 
HIV/AIDS in Tallahassee.  The most populated counties within the state have local 
ADAP offices based in the respective county health department to serve the nearby 
residents.  Smaller counties with lower numbers of HIV-infected patients are served via a 
central pharmacy in Tallahassee. Program policies and procedures are published in the 
ADAP Program Manual and serve as the operating standards for each ADAP office 
within the State (Florida Department of Health, 2007).   
The goals of the Florida ADAP are to: 1) establish a program to provide 
therapeutics to treat HIV disease or prevent deterioration of health arising from HIV; 2) 
provide access to HIV treatments for low income, indigent persons who have no other 
resource to attain needed medications; 3) facilitate access to the program; 4) provide 
outreach to individuals with HIV and their families; and 5) provide program and 
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procedural technical assistance and guidance to county health departments to facilitate 
service to eligible persons.   Two additional goals are explicitly related to adherence: 1) 
to help patients adhere to their treatment regimens and 2) to assist patients in avoiding 
interruption in ARV regimens (Florida Department of Health: Bureau of HIV/AIDS, 
2003).   
Many of the standards associated with the Florida ADAP are consistent with 
current recommendations and guidelines found in the Department of Health and Human 
Services (DHHS) treatment guidelines (National Institutes of Health, 2006).  For 
example, clinical eligibility to start antiretroviral therapy with the Florida ADAP mirrors 
the recommendations of the DHHS for initiation of HAART.  Similarly, the ADAP 
requires ongoing HIV RNA measurement and CD4 lymphocyte counts every three to 
four months to monitor response to treatment as recommended by the DHHS. 
Although the ADAP is primarily a medication access program, administrative 
functions incorporate actions to monitor and reinforce adherence to HAART.  The 
Florida ADAP Program Manual addresses a number of issues related to HAART 
adherence which are summarized in Table 5. 
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Table 5 
 
Adherence-Related Statements in the Florida ADAP Program Manual 
 
 
1. 
 
Any department-specified or local health department adherence policy and/or 
procedure must be followed in educating and counseling the patient about taking 
medications. 
 
2. If there are problems with adherence, especially if a change in the HAART regimen 
is due to nonadherence, the patient's case manager and healthcare provider should 
be notified. 
   
3. Patients in the Florida ADAP may be disenrolled if the patient fails to pick up 
medications for more than 60 days and or is refusing to adhere to the medication 
regimen despite counseling and supports or other assistance offered.  This decision 
should be made with the treating healthcare provider's input and guidance. 
 
4. Patients are responsible for picking up their medications on time each month before 
they run out.  
 
5. It is the goal of the ADAP to help patients adhere to their treatment regimens.   
 
6. Patients have to cooperate in picking up medication and providing required 
information as requested or required. 
 
Adapted from Florida Department of Health: Bureau of HIV/AIDS. (2003). AIDS Drug Assistance 
Program Manual (ADAP). Tallahassee: Florida Department of Health. 
 
The Florida ADAP Program Manual also addresses patients who are nonadherent 
to HAART.  Nonadherence is defined as not picking up HAART agents from the 
pharmacy within 35 days of the last pharmacy refill (Florida Department of Health: 
Bureau of HIV/AIDS, 2003).   The statements in Table 6 summarize the process that 
ADAP staff is expected to follow when a nonadherent patient is identified. 
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Table 6 
Florida ADAP Procedures Related to Nonadherence and Failure to Pick-up  
 
1. If the patient is five or more workdays late for a scheduled medication pickup: 
• An inquiry should be initiated to determine the reason for the delay in picking up 
medications. 
• The case manager and treating healthcare provider must be notified as soon as possible. 
• A determination should be made as to whether or not the patient has had an interruption in 
drug therapy.  If the patient last picked up a 30 day supply of medication, and has not been 
back to pick up for 35 or more days, then there has been an interruption in therapy. 
• If there has been no interruption in drug therapy, the patient should be encouraged and 
assisted in getting his or her medications for the month. 
• If there has been an interruption in drug therapy of five or more days, a consultation with the 
treating healthcare provider should be made as soon as possible before the patient is allowed 
to pick up his or her medications for the month.  
2. Patients who report "borrowing" or using another patient's medications to continue their own 
treatment are still considered to have an interruption in therapy if medications were issued by the 
Department more than 35 days prior. 
• Patients who report using "leftover" medications in their possession also may have been 
nonadherent. 
• Patients should not be given medications until the healthcare provider has been consulted 
and has given approval to issue medications or other instructions. 
3. If the patient fails to show at all for three weeks to 30 or more days to pick up medications, the 
treating healthcare provider and case manager must be notified.   
• If the patient comes in for medication at this point, he or she must see the treating healthcare 
provider before being given medication. 
• If the treating healthcare provider states that an office visit is not needed or desired, and 
wants medication issued, give the patient medications and document the name of the 
healthcare provider's staff who gave the instruction to issue the medications. 
4. If the patient fails to show at all for 60 days or more, he or she should be closed out of the ADAP 
system.   
• Notify the case manager and the healthcare provider that the patient has not picked up 
medication for 60 days prior to closure. 
• If the patient shows up in 60 days and has not been closed, he or she must see the treating 
healthcare provider, have new labs, and obtain prescriptions. 
5. If the patient has missed 90 days or more of medication, has not already been closed out, and comes 
in, no medications can be given.   
• The patient must see the treating healthcare provider, provide new labs and obtain new 
prescriptions. 
• Notify the healthcare provider and the case manager that the patient has missed 90 days of 
medication. 
6. Documentation of contact with the patient and the healthcare provider must be placed in the patient 
record.   
• Patients who decide to stop drug therapy without the knowledge or consent of their treating 
healthcare provider should be advised to contact him or her. 
• Notice of therapy interruption should be given to the healthcare provider by the ADAP 
contact. 
 
Adapted from Florida Department of Health: Bureau of HIV/AIDS. (2003). AIDS Drug Assistance 
Program Manual (ADAP). Tallahassee: Florida Department of Health. 
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The Florida ADAP is unique with their approach to closely and regularly monitor 
medication refill adherence as part of the program’s standard of practice. ADAP staff 
records the date that patients pick up their medications from the pharmacy in each 
patient’s record.  The program provides a 30 day maximum supply of ARV medication.  
Prescriptions can be refilled 28-35 days after the previous prescription has been 
dispensed.  Programmatic standards state that if the patient is five or more workdays late 
for a scheduled medication pickup, an inquiry should be initiated to determine the reason 
for the delay in picking up medications.  The case manager and treating healthcare 
provider must be notified as soon as possible.  A determination should be made as to 
whether or not the patient has had an interruption in drug therapy which they define as a 
time lapse of 35 or more days since the patient last picked up a 30 day supply of 
medication (Florida Department of Health: Bureau of HIV/AIDS, 2003).   
If there has been no interruption in drug therapy, the patient is encouraged and 
assisted in getting his or her next supply of monthly medications.  If there has been an 
interruption in drug therapy of five or more days, a consultation with the treating 
healthcare provider is made as soon as possible before the patient is allowed to pick up 
his or her medications for the month.  The treating healthcare provider can either approve 
additional medication dispensing or hold further medication dispensing.  If dispensing is 
put on hold, the healthcare provider usually schedules a face-to-face meeting with the 
patient or requires that the patient schedule an appointment with the adherence specialist 
for additional assessment and intervention.  It is this medication refill monitoring process 
that serves as the main monitoring component for the structured adherence intervention in 
this study. 
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Usual Care 
Usual care in this study included patients that received their antiretroviral therapy 
from Florida Medicaid.  Like the ADAP, this program also provided a 30 day supply of 
medication but did not contain procedural or administrative conditions which could 
impact adherence.   Healthcare providers were not informed of missed or late pharmacy 
refills.  It is theoretically possible that a patient could fail to pick-up any medication or 
could pick up medication refills erratically without the prescriber’s knowledge. 
Medication Adherence Assessment 
Providers of the outpatient HIV treatment program monitor self-reported 
medication adherence at each clinic visit for patients participating in the ADAP and usual 
care programs.   During the routine clinic intake process, a medical assistant asks each 
patient several adherence related questions and documents responses on a clinic-designed 
Medication Adherence Assessment Form.  Although no validity or reliability testing has 
been performed on this specific assessment tool, self-reported adherence based on patient 
recall of the number of doses missed in the last 7-30 days has been reported in the 
literature as a valid indicator of adherence (Haubrich et al., 1999; Mannheimer, 
Friedland, Matts, Child, & Chesney, 2002; Montaner et al., 1998; Nieuwkerk & Oort, 
2005).   These self-report adherence questions are listed in Table 7. 
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Table 7 
 
Medication Adherence Assessment Questions (Self-Report) 
 
 
1. 
 
How many doses of your HIV medication have you missed in the last week (7 days)? 
 
2. 
 
How many doses of your HIV medication have you missed in the last month (30 days)? 
3. Are you having any side effects from your HIV medications that interfere with your ability 
to take them on a regular basis? 
 
  
Using the patient’s response to the medication adherence assessment, the provider 
calculated an adherence rate for each patient.  The monthly adherence rate was calculated 
as:  (1 – [missed doses in the last 30 days / prescribed doses in the last 30 days] ) X 
100%.  This percentage was documented in the patient’s medical record and was 
subsequently entered into the LabTacker™ database by a data entry assistant.   
Adherence Services and Interventions 
The outpatient HIV treatment program employs a registered nurse in the capacity 
of adherence specialist.  The adherence specialist was available to all patients that 
received care at the outpatient HIV treatment program including ADAP and usual care 
patients.  While most patients are referred to the adherence specialist from their 
healthcare provider, patients can also self-refer to the specialist for assistance.  ADAP 
staff also refers patients to the adherence specialist when they identify a perceived need 
for adherence assessment or intervention.  Typical services and interventions provided by 
the adherence specialist are summarized in Table 8. 
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Table 8 
 
Services and Interventions Provided by the Adherence Specialist 
 
 
• General education related to the HIV disease process, HIV treatment medications and goals of 
treatment 
 
• General and specific information related to ARV medications including dosing, timing, 
potential side effects and side effect management 
 
• Medication scheduling assistance 
 
• Education related to the importance of adherence, methods to prevent the development of ARV 
resistance, and pharmacy and medication refill processes 
 
• Assessment of support systems 
 
• Identification of potential barriers to adherence 
 
• Support and counseling 
 
• Prescription of adherence aids: pill boxes, timers, alarm watches 
 
 
Adherence interventions may include the recommendation to use a pill box, the 
use of a programmable wristwatch which can display multiple digital messages to serve 
as reminders throughout the day, reminder telephone calls, education, counseling, and 
support.  All services and materials are provided free of charge to the patient as they are 
provided by Ryan White Grant funding and donations.   
Documentation of adherence assessment and intervention is documented in the 
clinic medical record along with the length of the visit in increments of 15 minute 
sessions.   The adherence specialist maintains a Microsoft® Access database containing 
the patient’s self-reported adherence percentage, number of visits for adherence 
counseling, length of time associated with each consultation, and interventions or aids 
that were provided or recommended to the patient.
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Summary 
The Florida ADAP includes a unique structured adherence intervention as a 
standard component within their medication access program.  Pharmacy refill data is 
closely monitored by ADAP staff with the intent that patients will refill their medication 
on time, month after month.  After picking up a month’s supply of HAART medications, 
patients have approximately a one-week period to refill their next month’s supply 
beginning at day 28 and ending at day 35.  ADAP staff is in close contact with pharmacy, 
medical, and nursing staff to keep everyone proactively informed of patients that may 
have adherence deficits.  Patients who do not pick up monthly refills within the 
appropriate timeframe are required to consult with the healthcare provider who may grant 
permission to resume medication or may require the patient to consult with the adherence 
specialist for further assessment and possible intervention.  This structured adherence 
process served as the primary intervention in this research study. 
Research Design 
Study Design 
This study used a retrospective comparative design to analyze secondary data.   
The study was designed to better understand the effects of a structured adherence 
intervention associated with an existing medication access program on adherence to 
HAART and response to HAART treatment compared to usual care. In the SAI group, 
providers closely monitored monthly HAART medication refills and provided structured 
adherence intervention when indicated.  Patients in the usual care group were enrolled in 
a Medicaid-funded medication access program and did not receive ongoing medication 
refill monitoring and structured adherence intervention.   
   
 
 
 
68
Study Population 
The study population included all eligible patients participating in the Florida 
ADAP or in a Medicaid-funded medication access program who received HAART 
medications and outpatient HIV medical care from one single treatment center and 
pharmacy in west central Florida during the calendar year 2005.  This time period was 
selected to minimize the influence of the implementation of Medicare Part D prescription 
medication coverage which was initiated in January 2006.  The implementation of 
Medicare Part D prescription drug coverage had the potential to introduce additional 
confounders as the process was complicated for patients and staff, and resulted in 
difficulty in accessing medication for many individuals.    
Inclusion Criteria 
Included were all patients 18 years of age or older who completed a minimum of 
six consecutive months in the SAI or usual care program as the sole means of obtaining 
HAART medications during calendar year 2005 while on a consistent HAART regimen.  
All patients received their medication from the single pharmacy associated with the HIV 
treatment center.  
Exclusion Criteria 
Exclusion criteria included less than six months of consecutive participation in the 
SAI program or usual care program, alterations to the ARV regimen during the six-month 
period, or use of a pharmacy other than the on-site pharmacy. 
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Sample Size 
This study used secondary data and the sample size was fixed.  A preliminary 
query of the database suggested there were 1,355 potential subjects eligible for 
evaluation. Of these, 37% composed the usual care group while 63% composed the SAI 
group.   
Since the exact number of patients meeting the inclusion criteria was not initially 
known, a conservative estimate of 50% (n=678) was considered for the purpose of 
establishing a power analysis.  Results of the analysis using this conservative estimate 
should ensure that there is adequate power to conduct the proposed analyses.  Results of 
the power analysis for more liberal estimates of 60% and 70% of the entire population are 
also provided to demonstrate the increased power available for the study should these 
situations be found in the data.   
Power Analysis 
Power estimates were derived for multivariable logistic regression, the least 
powerful and most complex of the analyses proposed in this study, thereby ensuring 
adequate sample size for all of the analyses in the study. Table 9 summarizes the 
estimated range of possible subjects and the respective power analysis associated with the 
estimate.  Power analyses were also conducted using inclusion estimates of both 60% and 
70%.  The power estimates are displayed in Table 9. 
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Table 9 
Power Estimates Based on Projected Sample Population 
 
Database  
Population (N) 
Percentage of Database 
Meeting Inclusion Criteria 
Sample Size 
(N) 
Power 
 
 
1,355 50% 678 0.80 
1,355 60% 813 0.86 
1,355 70% 949 0.91 
 
Because of the unique nature of this study, no data were found in the literature to 
suggest an appropriate effect size for this study.  Therefore, effect size was chosen based 
on programmatically relevant changes. For this analysis a 10% improvement response to 
treatment by patients in the SAI program compared to those in the usual care program 
was identified as being programmatically relevant.  Based on this assumption, a 
minimum sample size of 678 patients achieves a power of .80 at the .05 level of 
significance when expecting a .10 effect.  The power analysis was conducted using the 
Power Analysis and Sample Size (PASS) statistical program (Hintz, 2001). 
Setting 
 All patients considered for this study were enrolled in a comprehensive outpatient 
HIV care program in west central Florida. This center was established in 1989 and is the 
largest single public provider of HIV care on the west coast of Florida.  The center serves 
approximately 1500 active patients.  The clinic provides multiple services including 
medical and nursing care for patients with HIV disease along with pharmacy, dental, and 
social services.   
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Most patients were seen by their HIV care provider every one to three months.  
Most patients obtained their medications at the on-site pharmacy.  All medications 
dispensed from the pharmacy were limited to a 30-day supply requiring prescriptions to 
be refilled on a monthly basis. 
Study Variables 
Dependent Variables 
There are two outcome variables in this study: adherence (self-reported 
medication adherence and pharmacy refill adherence) and treatment response (CD4 
lymphocyte response and HIV RNA response).  Although adherence could be considered 
a proximal outcome variable that influences treatment response, it was considered as a 
terminal outcome in this study.   
Self-reported medication adherence.  Satisfactory adherence is defined as 90% or 
more of the pills prescribed in any regimen taken in accordance with the prescription 
plan.  This is in agreement with the procedure from several other HIV medication 
adherence studies (Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 1999; Gross, Bilker, 
Friedman, & Strom, 2001).  All self-reported adherence levels collected during the study 
period were assessed. 
Pharmacy refill adherence.  Pharmacy prescription refill data is used as a 
surrogate for medication-taking behavior and typically compares actual versus expected 
refills.   Although this method does not guarantee that the medications were ingested, it 
does represent maximum probable adherence.  Refill adherence is calculated as the 
percentage of times the index ARV agent (protease inhibitor or non-nucleoside reverse 
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transcriptase inhibitor) was refilled by the pharmacy within the 28-35 day timeframe 
during the study period. 
CD4 lymphocyte response.  CD4 lymphocytes were measured by four commercial 
laboratories using flow cytometry and hematology analyzers using fresh blood 
specimens.   Test results indicated the number of CD4 cells per cubic millimeter of blood 
(Bartlett & Gallant, 2005).  Immunologic response to HAART treatment was measured as 
the change in CD4 lymphocyte count from baseline to 6 months.  A stable or increasing 
CD4 lymphocyte count is representative of successful HAART treatment. 
HIV RNA response.  Quantitative HIV RNA levels were measured by four 
commercial laboratories. Test results indicated the number of copies of HIV RNA per 1 
mL of plasma (Bartlett & Gallant, 2005).  Virologic response to HAART treatment was 
measured as the change in HIV RNA level from baseline to 6 months. An undetectable or 
decreasing HIV RNA level is representative of successful HAART treatment. 
Independent Variables: Treatment Conditions  
Group membership (SAI versus usual care) is the independent variable of interest 
in this study.  The usual care group for this study included patients using Medicaid to 
fund their HAART at the same on-site clinic pharmacy.  The Medicaid program did not 
include a specific adherence or prescription refill monitoring component.  A maximum 
30-day supply of medication was dispensed by the pharmacy at any one time.  The SAI 
includes a number of standard procedures to monitor and strengthen adherence as 
described earlier. 
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Independent Variables: Covariates 
Covariates include adherence services and intervention, ARV specific factors, 
self-reported medication adherence, pharmacy refill adherence, socio-demographic 
factors, and HIV disease specific factors. 
Adherence services and intervention.  The number of face-to-face visits with the 
adherence specialist during the study period, total length of time (in minutes) associated 
with these face-to-face visits, and prescription of adherence aids were assessed to 
compare the utilization of the adherence specialist’s services between the groups.   
ARV specific factors.  Characteristics related to the HAART regimen were 
assessed including dosing frequency (once vs. twice daily), type of regimen based on 
index agent (non-nucleoside reverse transcriptase-based vs. protease inhibitor-based), and 
pill burden defined as the number of HAART pills prescribed per day. 
Sociodemographic factors.  Sociodemographic variables included age, gender, 
race, ethnicity, income level, housing status, and health insurance.  
HIV disease specific factors.  These clinical covariates included risk factor for 
HIV transmission, the number of years diagnosed with HIV infection, stage of disease 
(HIV vs. AIDS), and the presence of comorbid conditions known to impact HAART 
adherence including the presence of active substance abuse and active mental health 
disorders (depression, bipolar disorder and anxiety disorder).    
Tables 10 and 11 list all variables considered in this study with detailed 
information related to the source of the data, frequency of measurement, operational 
definition and level of measurement. 
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Table 10 
Variables, Definitions and Measurement (Part I) 
 Source of 
Data 
Frequency Operational Definition / 
Measurement 
Level of 
Measurement
 
Dependent Variables 
Medication 
Adherence: 
Self Report 
LabTracker™ Month 0, 3 
and 6 
 
Self-reported number of ARV 
medication doses missed in the last 
7 days.  Adherence calculated as: (1 
– [missed doses / prescribed doses]) 
X 100%. Average adherence >/= 
90% = 1; <90% = 0.    
Nominal 
Medication 
Adherence: 
Pharmacy 
Refill 
Pharmacy 
administrative 
database 
Month 1, 
2, 3, 4, 5, 
6 
Percentage of times the index ARV 
medication (PI or NNRTI) was 
refilled by the pharmacy within the 
28-33 day timeframe during the six-
month study period. Average 
adherence >/= 90% = 1; <90% = 0.    
Nominal 
Immunologic 
Response: 
CD4 
Lymphocyte 
LabTracker™ Month 0, 6 Change in value from month 0-6. 
No change or increase = 1; 
Decrease = 0. 
Nominal 
Virologic 
Response: HIV 
RNA 
LabTracker™ Month 0, 6 Change in value from month 0-6.  
No change or decrease = 1;  
Increase = 0. 
Nominal 
 
Independent Variables   
Treatment Condition: Group Membership Structured Adherence Intervention 
or Usual Care 
Nominal 
Covariates 
 Sociodemographic Factors 
Gender LabTracker™ Baseline Male, Female, Transgender Nominal 
Age LabTracker™ Start of 
study 
period 
Age in years  Continuous 
Race LabTracker™ Baseline White, Black, Asian/Pacific 
Islander, Native American 
(Alaskan), Multiple 
Nominal 
Ethnicity LabTracker™ Baseline Hispanic,  Nominal 
Income level LabTracker™ Baseline < 100% FPL, 101-200% FPL, 
201-300% FPL, >300% FPL 
Ordinal 
Housing Status LabTracker™ Baseline Permanent, Nonpermanent Nominal 
Health 
Insurance 
LabTracker™ Each 
encounter 
 
None, Medicaid, Medicare,  
Medicaid and Medicare, 
Hillsborough HealthCare 
Nominal 
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Table 11 
 
Variables, Definitions and Measurement (Part II) 
 
 Source of 
Data 
Frequency Operational Definition / 
Measurement 
Level of 
Measurement
 
HIV Disease-Specific Factors 
HIV Risk 
Factor 
LabTracker™ Baseline MSM, Heterosexual, IDU, MSM 
and IDU, Tissue/Blood Transfusion, 
Hemophilia, Perinatal, Unknown 
Nominal 
Disease Stage LabTracker™ Baseline  Number of years the subject has 
been living with HIV Disease 
calculated as length of time from 
the first HIV-positive antibody test 
to the date of study entry 
Interval 
HIV Disease 
Status 
LabTracker™ Once 
(study 
entry) 
HIV or AIDS Nominal 
Active 
substance 
abuse 
LabTracker™ Month 
1,2,3,4,5,6 
Yes, No Nominal 
Presence of 
MH disorder 
LabTracker™ Month 
1,2,3,4,5,6 
Yes, No Nominal 
 
ARV Specific Factors 
Dosing 
frequency 
LabTracker™ Baseline  One daily, twice daily Nominal 
Type of 
regimen 
LabTracker™ Baseline PI based, NNRTI based Nominal 
Daily pill 
burden 
LabTracker™ Baseline  Number of total ARV pills taken 
per day 
Continuous 
 
Adherence Services and Intervention  
Number of 
Face-to-face 
adherence 
counseling 
visits 
Adherence 
database 
Month 
1,2,3,4,5,6 
Number of face-to-face visits with 
Adherence Specialist during study 
period. 
Continuous 
Time 
associated with  
face-to-face 
adherence 
counseling 
Adherence 
database 
Month 
1,2,3,4,5,6 
Total time in minutes of face-to-
face visits with Adherence 
Specialist 
Continuous 
Adherence aids 
prescribed 
Adherence 
database 
Month 
1,2,3,4,5,6 
Yes/No Nominal 
 
 
   
 
 
 
76
  
Data Sources 
Data were obtained from several electronic databases.  This section will review 
the data sources, validity of data, methods associated with the process of obtaining de-
identified data, data management, and security.  
LabTracker™ (Ground Zero Software, 2007) software has been used as the 
primary database for clinical and administrative data for over four years. 
Sociodemographic data are reassessed at the patient’s first outpatient visit in each 
calendar year by an advanced registered nurse practitioner or a physician.  These data are 
subsequently entered and updated in the LabTracker™ system by two dedicated data 
entry assistants.  Validity of data is continually monitored by a registered nurse and an 
advanced registered nurse practitioner who compare Lab Tracker™ data to medical 
record data and laboratory report forms to assure congruence.  Accuracy of data is 
externally audited twice a year by two independent agencies to assure accuracy of 
recorded data and has consistently been 97-100% accurate when compared to medical 
record data and laboratory reports.    
Pharmacy data was stored in the Pharmacy Management System (PMS) (Etreby 
Computer Company, 2007).  Data was entered by clinical pharmacists and pharmacy 
technicians and was verified by the supervising pharmacist on an ongoing basis.  Data is 
externally audited for accurateness annually and has consistently been 95-100% accurate.   
A Microsoft® Access database contained the adherence specialists’ utilization 
data associated with each patient.  Data was entered by a registered nurse working in the 
capacity as an adherence specialist.   Accuracy of the data is externally audited once a 
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year by an independent agency to assess accuracy of recorded data and has consistently 
been 98-100% accurate when compared to medical record data.   
Data Collection Procedures 
 The health center administrator (HCA) at the clinical facility had complete access 
to the LabTracker™, Pharmacy Management System, and adherence specialist data 
bases.  Information from all three data bases was initially linked by a four digit unique 
internal identification number that is used throughout the clinical facility.  Once the HCA 
matched all data into one Microsoft® Excel file, the unique internal client identifier was 
replaced with a randomly generated study code using Microsoft Excel’s random number 
generating program.   Once the files were matched, the randomly assigned study code 
number was assigned as the only means of identification, and the matching algorithm was 
destroyed by the HCA.   
The HCA provided the investigator with a Microsoft® Excel file containing all 
data elements and variables identified in this study. The resulting data file had no direct 
or indirect links that could identify any individual participant or group of participants.   
Procedures 
Institutional Review Boards 
 Approvals for Institutional Review Board (IRB) exemption were obtained from 
the University of South Florida’s Office of Research, Division of Research Compliance 
IRB (Appendix A) and the Florida Department of Health IRB (Appendix B).  Exemption 
from the IRB was granted because the study used existing data, documents, and records 
that were recorded without identifiers. 
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Letter of Support 
 A letter indicating support for the study was obtained from the director of the 
clinical facility. 
Data Management 
The Statistical Package for the Social Sciences (SPSS) version 15.0 was used for 
data analysis and data management.  The data files were housed on a dual-password-
protected network server at the clinical site with access only by the researcher and 
research assistant. 
Missing Data 
Incomplete or missing sociodemographic information, HIV disease specific 
factors, and ARV specific factors are highly unlikely as these elements are mandatory in 
the LabTracker database. While missing laboratory data is also unlikely, missing CD4 
lymphocyte counts and HIV RNA levels will be imputed using the mean value of a 
subject’s laboratory data collected in the study period. 
Data Analysis Plan 
The effects of the SAI will be assessed by testing two hypotheses.  The following 
section describes the data analyses methods. 
Hypothesis 1: Patients participating in the SAI will have higher levels of self-
reported and pharmacy refill adherence compared to patients receiving usual care. 
Hypothesis 2:  Patients participating in the SAI program will have better 
immunologic (CD4 lymphocyte) and virologic (HIV RNA) responses to HAART 
compared to those receiving usual care. 
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Frequency distributions and descriptive statistics on all variables were performed 
to describe the study sample. There were two outcome variables in the study: adherence 
and treatment response. 
A series of bivariate analyses were conducted to investigate the relationship 
between self-reported adherence and pharmacy refill adherence, group membership (SAI 
vs. usual care) and the covariates in the study.  Variables found to be independently 
associated with adherence were considered for inclusion in a regression model.   Logistic 
regression was performed on the outcome variables to test the effects of the treatment 
condition while controlling for adherence services and intervention, HIV disease specific 
factors, ARV specific factors and sociodemographic factors. 
A series of bivariate analyses were conducted to investigate the relationship 
between CD4 lymphocyte response and HIV RNA response, treatment conditions (SAI 
vs. usual care) and the covariates in the study.  Logistic regression was performed on 
CD4 lymphocyte response and HIV RNA response to test the effects of the treatment 
condition while controlling for HIV disease specific factors, ARV specific factors and 
sociodemographic factors. 
 Results of the study were reported as group data and no identifying information 
related to any person is presented. 
Summary 
Chapter 3 described the operating standards within the Florida ADAP that serve 
as a structured adherence intervention for patients receiving HAART and the Medicaid 
program that serves as the usual care group. The adherence assessment and intervention 
   
 
 
 
80
processes, study design, population, setting, variables and data collection procedures 
were described.  Finally, the data analysis plan was summarized. 
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CHAPTER 4: FINDINGS 
This chapter presents the results of this study.  Following a description of the 
sample and comparison of the study groups, the results of the bivariate and logistic 
regression analyses are reported.   
Study Sample 
The initial query of the LabTracker™ database suggested 1,355 potential subjects 
eligible for analysis. After inclusion and exclusion criteria were applied, 424 subjects 
were eligible for analyses.  The SAI group included 204 subjects (48%) while 220 
subjects (52%) in the usual care group were eligible for inclusion.   
Subjects Excluded from Analysis 
A total of 931 subjects did not meet inclusion criteria for this study. This number 
was higher than expected. The reasons for excluding these subjects are shown in Table 
12.  The primary reason for exclusion was not using the on-site pharmacy for ARV 
medication access.  Patients with Medicaid or commercial insurance could select any 
community pharmacy to obtain medication. Although the usual care group in this study 
also had the potential to use any community pharmacy, subjects elected to use the on-site 
pharmacy at the study site.   
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Table 12 
Subjects Excluded from Study 
 
 
Reason for Exclusion 
 
Number Excluded (%) 
 
 
Not receiving antiretroviral therapy from the on-site 
pharmacy 
 
565 (60.7) 
  
Not prescribed antiretroviral therapy for at least 6 
consecutive months 
291 (31.2) 
  
Missing data 49 (5.3) 
 
Death during the first seven months of year 2005 
 
26 (2.8) 
Note: N = 931 
 
In theory, these two populations should be similar with regard to socio-
demographic, HIV disease characteristics and comorbid conditions.   Sociodemographic 
variables were available for 547 of 565 patients who did not use the on-site pharmacy. 
These variables were examined using Pearson Chi-Square analysis to identify differences 
between the usual care group of subjects and the subjects excluded from the study 
because they did not use the on-site pharmacy. No significant differences were found 
between or among the two groups.  This information is displayed in Table 13. 
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Table 13 
Comparison of Sociodemographic Characteristics of SAI Group, Usual Care Group and 
Subjects Not Meeting Inclusion Criteria 
 
    
SAI  
  
Usual 
 Care   
Excluded from 
Study 
 Total 
 
  
n=204 
Frequency (%)  
n=220 
Frequency (%)  
n=547 
Frequency (%)  
N971 
Frequency (%) 
Gender                     
 Male 152 (74.5)  147 (66.8)  366 (66.9)  665 (68.5) 
 Female 52 (25.5)  73 (33.2)  181 (33.1)  306 (31.5) 
                        
Race                     
 White 123 (60.3)  106 (48.2)  264 (48.3)  493 (50.8) 
 Black 76 (37.3)  110 (50.0)  272 (49.7)  458 (47.2) 
 Other 5 (2.5)  4 (1.8)  11 (2.0)  20 (2.1) 
                        
Ethnicity                     
 Non-Hispanic 144 (70.6)  165 (75.0)  414 (75.7)  723 (74.5) 
 Hispanic 60 (29.4)  55 (25.0)  133 (24.3)  248 (25.5) 
                       
Age at time of study (years) 
                 
 18-29 22 (10.8)  9 (4.1)  24 (4.4)  55 (5.7)
 30-39 52 (25.5)  42 (19.1)  107 (19.6)  201 (20.7)
 40-49 79 (38.7)  99 (45.0)  245 (44.8)  423 (43.6)
 50-59 46 (22.5)  52 (23.6)  128 (23.4)  226 (23.3)
 > 60 5 (2.5)  18 (8.2)  43 (7.9)  66 (6.8)
                       
Health Insurance                  
 Yes 69 (33.8)  219 (99.5)  539 (98.5)  827 (85.2) 
 No 135 (66.2)  1 (0.5)  9 (1.6)  145 (14.9) 
                         
Income Level (%FPL)                    
 <100% 124 (60.8)  168 (76.4)  419 (76.6)  711 (73.2) 
 101-200% 55 (27.0)  46 (20.9)  111 (20.3)  212 (21.8) 
 >200% 25 (12.3)  6 (2.7)  17 (3.1)  48 (4.9) 
             
Housing Status                      
 Permanent 201 (98.5)  215 (97.7)  534 (97.6)  950 (97.8) 
  
Nonpermanent 
 
3 
 
(1.5) 
  
5 (2.3) 
   
13 (2.4) 
   
21 
 
(2.2) 
 
 
HIV disease specific characteristics and comorbid conditions were also compared 
between the subjects in the usual care group and the subjects excluded from the study.  
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These variables were examined using Pearson Chi-Square analysis to identify differences 
between the usual care group of subjects and the subjects excluded from the study 
because they did not use the on-site pharmacy. No significant differences were found 
between the two groups. Table 14 displays this information.   
 
Table 14 
HIV Disease and Comorbid Conditions - Characteristics of SAI Group, Usual Care 
Group and Subjects Not Meeting Inclusion Criteria 
 
  SAI  Usual Care  Excluded  Total  
  
n=204 
Frequency (%)  
n=220 
Frequency (%)  
n=547 
Frequency (%)  
n=971 
Frequency (%)
HIV Disease Status        
 
HIV (non-
AIDS) 87 (42.6)  68 (30.9)  172 (31.4)  327 (33.7) 
 AIDS 117 (57.4)  152 (69.1)  375 (68.6)  644 (66.3) 
             
HIV Risk Factor           
 MSM 85 (41.7)  61 (27.7)  152 (27.8)  298 (30.7) 
 Heterosexual 106 (52.0)  127 (57.7)  319 (58.3)  552 (56.8) 
 IDU 10 (4.9)  26 (11.8)  63 (11.5)  99 (10.2) 
 Other 3 (1.5)  6 (2.7)  13 (2.4)  22 (2.3) 
             
Presence of Active Substance Abuse       
 Yes 18 (8.8)  25 (11.4)  67 (12.2)  110 (11.3) 
 No 186 (91.2)  195 (88.6)  480 (87.8)  861 (88.7) 
             
Presence of Active MH Disorder        
 Yes 54 (26.5)  65 (29.5)  162 (29.6)  281 (28.9) 
 No 150 (73.5)  155 (70.5)  385 (70.4)  690 (71.1) 
        
 
 In summary, the sociodemographic, HIV disease, and comorbid characteristics 
between the usual care group and the group excluded from the study were approximately 
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equivalent.  Chi-square tests were performed to look for significant differences in 
characteristics between these groups.  No significant differences were found.  
Characteristics of the Study Sample 
The mean age of the sample was 44.3 years with a range of 19-76 years (SD: 9.36 
years). The majority of subjects in the sample were men (n=299; 70.5%) and self-
identified as non-Hispanic (n=309, 72.9%).  The majority of the subjects were white 
(n=229, 54%) and 186 (43.9%) were black.  The primary risk factors associated with HIV 
infection for the sample were (a) heterosexual (n=233, 55%); (b) men having sex with 
men (n=146, 34.4%); and (c) injection drug use (n=36, 8.5%).  The mean time living with 
HIV disease was 7.6 years with a range of 1-25 years.  The most common ARV regimen 
in the sample was protease inhibitor based (n=235; 55.4%).  Subjects had a daily pill 
burden range from 2 to 15 pills per day with a mean daily pill burden of 5.  
The SAI group included higher percentages of both younger patients (19-29 
years) and patients in the 50-59 year age range.  These differences were significant (Chi-
square 15.897, df 4, p=.003).  A higher percentage of white patients were seen in the SAI 
group while the usual care group included a higher percentage of black subjects.  These 
differences were significant (Chi square 6.994; df 2, p=.03).  Table 15 displays the 
frequency and percent for the demographic factors (gender, race, ethnicity, and age) of 
the patients who met inclusion criteria. 
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Table 15 
Sociodemographic Composition of the Study Groups 
 
 
Characteristics 
SAI 
n =  204 
Frequency (percent) 
Usual Care 
n = 220 
Frequency (percent) 
Total 
N = 424 
Frequency (percent) 
 
Gender 
     Male 
     Female 
 
 
152 
52
 
 
(74.5) 
(25.5) 
 
 
147 
73
 
 
(66.8) 
(33.2) 
 
 
299 
125 
 
 
(70.5) 
(29.5) 
 
Race * 
     White 
     Black 
     Other 
 
 
123 
76 
5
 
 
(60.3) 
(37.3) 
(2.5) 
 
 
106 
110 
4
 
 
(48.2) 
(50.0) 
(1.8) 
 
 
229 
186 
9 
 
 
(54.0) 
(43.9) 
(2.1) 
 
Ethnicity 
     Non-Hispanic 
     Hispanic 
 
 
144 
60
 
 
(70.6) 
(29.4) 
 
 
165 
55
 
 
(75) 
(25) 
 
 
309 
115 
 
 
(72.9) 
(27.1) 
 
Age at time of study (years)** 
     19-29 
     30-39 
     40-49 
     50-59 
     > 60  
 
 
22 
52 
79 
46 
5
 
 
(10.8) 
(25.5) 
(38.7) 
(22.5) 
(2.5) 
 
 
9 
42 
99 
52 
18
 
 
(4.1) 
(19.1) 
(45.0) 
(3.6) 
(8.2) 
 
 
31 
94 
179 
98 
23 
 
 
(7.3) 
(22.2) 
(42.0) 
(23.1) 
(5.4) 
 
Note.*=p<.05; **=p<.01 
 
Preliminary analyses demonstrated that several covariates had small cell sizes.  
Consequently several covariates were collapsed into fewer categories to provide the 
reader with more useful information related to the population.  Age of the participants 
was collapsed from a continuous variable to an ordinal variable with 5 age groups.  
Income levels were reduced from four groups to three due to small sample size in the 
upper income range.  Three male transgender patients were grouped as male.  Several 
HIV risk factors were grouped as “other” due to small cell sizes.  Finally, the number of 
years living with HIV disease was collapsed into four groups.  
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Health and Income Related Characteristics 
Table 16 displays the frequency for housing factors, health insurance, income, and 
HIV disease specific information.  As expected, a higher percentage of subjects in the 
usual care group had health insurance while subjects in the SAI relied on the ADAP to 
fund their medication. These differences were significant (Chi-Square 109.849, df 1, 
p<.0005).  More subjects in the usual care group had lower income (<100 FPL) while a 
higher percentage of subjects in the SAI had higher income (>200% FPL).  These 
differences were also significant (Chi-Square 18.5, df 2, p<.0005).  There was a higher 
percentage of subjects with a risk factor of MSM in the SAI and a higher percentage of 
IDUs in the usual care group (Chi-square 13.364, df 3, p=.004).  Lastly, there was a 
higher percentage of patients with an AIDS diagnosis in the usual care group (Chi-Square 
6.288, df 1, p=.012).   
Substance Abuse and Mental Health Disorders 
 Table 17 displays the frequency and percentage of patients diagnosed as having 
an active substance abuse problem or a mental health disorder (depression, bipolar 
disorder, or anxiety).  The SAI group and usual care group were approximately 
equivalent.  A total of 43 patients (10.1%) were identified as having an active substance 
abuse problem while 119 (28.1%) were diagnosed as having mental health disorder. 
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Table 16 
Health and Income Related Characteristics of the Study Group 
 
 
 
Characteristics 
 
SAI 
n =  204  
Frequency (percent) 
 
Usual Care 
n = 220 
Frequency (percent) 
 
Total 
N = 424 
Frequency (percent) 
 
Housing Status 
     Permanent 
     Nonpermanent 
 
 
201 
3
 
 
(98.5) 
(1.5) 
 
 
215 
5
 
 
(97.7) 
(2.3) 
 
 
 
416 
8 
 
 
(98.1) 
(1.9) 
 
HIV Risk Factor** 
     MSM 
     Heterosexual 
     IDU 
     Other 
 
 
 
85 
106 
10 
3
 
 
(41.6) 
(52.0) 
(4.9) 
(1.5) 
 
 
61 
127 
26 
6 
 
 
(27.8) 
(57.7) 
(11.8) 
(2.7) 
 
 
146 
233 
36 
9 
 
 
 
(34.4) 
(55.0) 
(8.5) 
(2.1) 
Years Living with HIV 
     <5  
     6-10 
     11-15 
      >15 
 
 
88 
55 
36 
25
 
(43.1) 
(27.0) 
(17.6) 
(12.3) 
 
89 
73 
41 
17
 
(40.5) 
(33.2) 
(18.6) 
(7.7) 
 
177 
128 
77 
42 
 
(42.7) 
(30.2) 
(18.2) 
(9.9) 
 
Income Level ***  
(% Federal Poverty Level) 
     <100 % 
     101-200 % 
     > 200 % 
 
 
 
124 
55 
25
 
 
 
(60.8) 
(27.0) 
(12.2) 
 
 
 
168 
46 
6 
 
 
 
(76.3) 
(21.0) 
(2.7) 
 
 
 
292 
101 
31 
 
 
 
(68.9) 
(23.8) 
(7.3) 
 
Health Insurance*** 
     Yes 
     No 
 
 
69 
135
 
 
(33.8) 
(66.2) 
 
 
219 
1
 
 
(99.5) 
(0.5) 
 
 
 
288 
136 
 
 
(67.9) 
(32.1) 
HIV Disease Status* 
     HIV (non-AIDS) 
     AIDS 
 
87 
117
 
(42.6) 
(57.4) 
 
68 
152
 
(30.9) 
(69.1) 
 
 
155 
269 
 
(36.6) 
(63.4) 
Note.*=p<.05; **=p<.01; ***p<.001 
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Table 17 
Substance Abuse and Mental Health Disorders in Study Group 
 
 
Characteristics 
 
SAI 
n =  204 
Frequency (percent) 
 
Usual Care 
n = 220 
Frequency (percent) 
 
Total 
N = 424 
Frequency (percent) 
 
History of Active 
Substance Abuse 
     Yes 
     No 
18
186
 
 
 
(8.8) 
(91.2) 
25
195
 
 
 
(11.4) 
(88.6) 
 
 
 
43 
381 
 
 
 
(10.1) 
(89.9) 
Presence of  Mental 
Health Disorder 
     Yes 
     No 
54
150
 
 
(26.5) 
(73.5) 
65
155
 
 
(29.5) 
(70.5) 
 
 
 
119 
305 
 
 
(28.1) 
(71.9) 
 
 
 
 
ARV Therapy Characteristics 
Table 18 describes the use of antiretroviral therapy associated with the study 
population.  There was a significant difference between the groups related to the type of 
ARV regimen subjects received (Chi-Square: 7.672, df 2, p=.022).  More than half of the 
patients in each group received a protease inhibitor-based regimen.  Approximately 6% 
of all patients received a non-nucleoside reverse transcriptase inhibitor (NNRTI) based 
regimen during the study period with a higher percentage in the SAI group.  Based on the 
DHHS guidelines in place during 2005, triple-NRTI regimens were not recommended 
regimens (National Institutes of Health, 2006).  
The mean daily pill burden was 5.4 pills per day with a range of 2-15 pills per 
day.   Over two-thirds of all patients received a regimen that required twice-daily dosing.   
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Table 18 
Use of Antiretroviral Medications in Study Groups 
 
 
Characteristics 
 
SAI 
n =  204 
Frequency (percent) 
 
 
Usual Care 
n = 220 
Frequency (percent) 
 
 
Total 
N = 424 
Frequency (percent) 
 
 
Type of Regimen* 
     Protease Inhibitor 
     NNRTI 
     Triple NRTI 
 
 
112 
74 
18
 
 
(54.9) 
(36.3) 
  (8.8) 
 
 
123 
91 
6
 
 
(55.9) 
(41.4) 
  (2.7) 
 
 
 
235 
165 
24 
 
 
 
(55.4) 
(38.9) 
(5.7) 
Dosing Frequency 
     Once Daily      
     Twice Daily 
 
59 
145
 
(28.9) 
(71.1) 
 
73 
147
 `  
(33.2) 
(66.8) 
 
 
132 
292 
 
(31.1) 
(68.9) 
Daily ARV Pill Burden 
     2-4 
     5-8 
     9-15 
89
99
16
 
(43.6) 
(48.5) 
(7.8) 
84
105
31
 
(38.2) 
(47.7) 
(14.1) 
 
 
173 
204 
47 
 
(40.8) 
(48.1) 
(11.1) 
Note.*=p<.05 
 
Adherence Services and Intervention 
 The majority of the study population (92.7%) did not receive adherence 
counseling or intervention (n=393).  A total of 31 patients (7.3%) received at least one 
face-to-face counseling session with the adherence specialist.    Subjects received 
anywhere from one session to 23 sessions with a range of total counseling time from 30 
minutes to 1,230 minutes.  One outlier received 23 sessions with a cumulative counseling 
time of 1,230 minutes.  With this outlier removed from analysis, the range of counseling 
time was 30-360 minutes with a mean of 91 minutes.  Fewer than 4% of all patients 
received adherence aids such as pill boxes, customized medication schedules, and alarm 
watches (n=16).  There were no significant differences related to adherence services and 
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interventions between the SAI and usual care group.  Table 19 displays the frequency and 
percentages of adherence counseling services and interventions received by subjects.  
 
Table 19 
Adherence Services and Intervention 
 
Adherence Measures 
 
SAI 
n =  204 
Frequency (percent) 
 
Usual Care  
n = 220 
Frequency (percent) 
 
 
Total 
N = 424 
Frequency (percent) 
 
 
Received Adherence 
Counseling Session  
     Yes 
     No 
 
 
 
16 
188
 
 
  
 (7.8) 
(92.2) 
 
 
 
15 
205
 
 
 
  (6.8) 
(93.2) 
 
 
 
 
31 
393 
 
 
 
7.3 
92.7 
Adherence Counseling: 
(Minutes) 
     0 
     30-60 
     61-120 
     >120 
 
 
 
188 
5 
9 
2
 
 
(92.2) 
(2.5) 
(4.4) 
(1.0) 
 
 
205 
3 
7 
5
 
 
(93.2) 
(1.4) 
(3.2) 
(2.3) 
 
 
393 
8 
16 
7 
 
 
(92.7) 
(1.9) 
(3.8) 
(1.7) 
Number of Face-to-Face 
Adherence Counseling 
Sessions (per patient) 
 
     0 
     1 
     2 
     3 
     5 
     >5 
 
 
 
 
188 
12 
3 
1 
0 
0
 
 
 
 
(92.2) 
  (5.9) 
  (1.5)  
  (0.5) 
    0 
    0 
 
 
 
 
205 
11 
1 
1 
1 
1
 
 
 
 
(93.2) 
(  5.0) 
  (0.5) 
  (0.5) 
  (0.5) 
  (0.5) 
 
 
 
 
 
393 
23 
4 
2 
1 
1 
 
 
 
 
 
(92.7) 
(5.4) 
(0.9) 
(0.5) 
(0.2) 
(0.2) 
Adherence Aids Prescribed 
     Yes 
     No 
 
6 
198
 
 ( 2.9) 
(97.1) 
 
10 
210
 
  (4.5) 
(95.5) 
 
 
16 
408 
 
(3.8) 
(96.2) 
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Self-Reported and Pharmacy Refill Adherence 
Characteristics related to self-reported adherence and pharmacy refill adherence 
are summarized in Table 20.  Three hundred sixty-four patients (85.8%) self-reported 
medication adherence of at least 90% while 60 patients (14.2%) reported adherence rates 
less than 90%.   A higher percentage of subjects self-reported adherence rates > 90% in 
the SAI group.  There were significant differences between the two groups (Chi-
square:19.581, df 1, p<.0005).   
Overall, adherence levels of at least 90% as measured by pharmacy refill pick-up 
were lower than the self-report measurements.  A greater percentage of patients in the 
SAI group had pharmacy refill adherence rates > 90%.  These differences were 
significant (Chi-Square: 7.578, df 1, p=.006). 
 
Table 20 
Self-Reported Adherence and Pharmacy Refill Adherence 
 
Adherence Measures 
 
SAI 
Frequency (percent) 
n =  204 
 
Usual Care 
Frequency (percent) 
n = 220 
 
Total 
Frequency (percent) 
N = 424 
 
Self-Report Adherence*** 
     > 90% 
    <  90% 
 
 
191 
13
 
 
(93.6) 
(6.4) 
 
 
173 
47
 
 
(78.6) 
(21.4) 
 
 
 
364 
60 
 
 
(85.8) 
(14.2) 
Pharmacy Refill 
Adherence** 
     > 90% 
    <  90% 
 
 
120 
84
 
 
(58.8) 
(41.2) 
 
 
100 
120
 
 
(45.5) 
(54.5) 
 
 
220 
204 
 
 
(51.9) 
(48.1) 
 
Note. **=p< .01; ***p<.001 
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Treatment Response 
 The majority of subjects demonstrated a favorable (stable or increasing) CD4 
lymphocyte response (63.9%).  A higher percentage of these subjects were seen in the 
SAI group but this was not a statistically significant finding.  However, a significantly 
higher percentage of patients in the SAI (79.4%) demonstrated a favorable virologic 
response (stable or declining HIV RNA level) compared with 45.9% in the usual care 
group (Chi-square 50.442, df 1, p<.0005).  Table 21 depicts this information. 
 
Table 21 
Treatment Response by Group Membership  
 
Adherence Measures 
 
SAI 
Frequency (percent) 
n =  204 
 
Usual Care 
Frequency (percent) 
n = 220 
 
Total 
Frequency (percent) 
N = 424 
 
CD4 Lymphocyte Count  
     Stable or Increasing    
     Decreasing 
 
 
139 
65
 
 
(68.1) 
(31.9) 
 
 
132 
88
 
 
(60.0) 
(40.0) 
 
 
 
271 
153 
 
 
(63.9) 
(36.1) 
HIV RNA Response*** 
     Stable or Declining 
     Increasing 
 
162 
42
 
(79.4) 
(20.6) 
 
101 
119 
 
(45.9) 
(54.1) 
 
263 
161 
 
(62.0) 
(38.0) 
 
Note. ***p<.001 
 
Summary 
Bivariate and descriptive analyses related to the study groups and covariates have 
been presented.   Several statistically significant differences between the SAI and usual 
care group have been reported. 
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Bivariate Analyses and Logistic Regression 
The following section will describe the bivariate analyses and logistic regression 
associated with the study.  Initially a series of Chi-Square analyses were conducted to 
investigate the relationship between adherence outcomes (self-reported and pharmacy 
refill), treatment response (CD4 lymphocyte and HIV RNA), treatment conditions (SAI 
and usual care) and the covariates in the study.  Variables found to be independently 
associated with adherence or treatment response at a significance level of p = .10 or less 
were considered for inclusion in a regression model. 
Logistic regression was performed on each outcome variable (self-reported 
adherence, pharmacy refill adherence, CD4 lymphocyte response and HIV RNA 
response) to test the effects of the treatment condition while controlling for potentially 
confounding effects (adherence services and intervention, HIV disease specific factors, 
ARV specific factors and sociodemographic factors).   
All models were checked for high intercorrelation using collinearity diagnostics 
within SPSS. Tolerance values were satisfactory with no evidence of intercorrelation 
between covariates.  Singularity was assessed using SPSS.  Variance inflation factor 
values were all greater than 10 suggesting no evidence of singularity.  Omnibus tests of 
model coefficients were performed on each of the models and values <.05 were obtained. 
These findings suggest acceptable goodness of fit for the models.  Hosmer and 
Lemeshow tests were performed for each of the models and values >.05 were calculated.  
These findings also suggest support of the models. 
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Study Aim One: Adherence Outcomes 
 The purpose of the first study aim was to determine whether patients participating 
in the SAI program experienced higher levels of adherence compared to patients 
receiving usual care, controlling for adherence services and intervention, HIV disease-
specific factors, ARV-specific factors, and sociodemographic factors. Two hypotheses 
were tested:  
1) Patients participating in the SAI program will have higher levels of self-
reported adherence compared to patients receiving usual care, controlling 
for selected covariates. 
2) Patients participating in the SAI program will have higher levels of 
pharmacy refill adherence compared to patients receiving usual care, 
controlling for selected covariates. 
 
Self-Reported Adherence 
Bivariate analyses were calculated on self-reported adherence and each of the 
covariates and the treatment condition.  The data are displayed in Tables 22 and 23.  
There were several significant findings.  Approximately 65% of patients who had health 
insurance self-reported adherence rates of at least 90% while a higher percentage (81.7%) 
of subjects without insurance self-reported adherence levels > 90%.  Individuals who 
reported acquisition of HIV infection associated with intravenous drug use (IDU) route 
had lower self-reported medication adherence while the men who have sex with men 
(MSM) group reported higher levels.  A higher percentage of subjects that did not have a 
history of active substance abuse (91.2%) self-reported adherence levels > 90% compared 
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to those with active substance abuse (81.7%).  Finally, subjects with a history of mental 
health disorders self-reported a higher percentage of medication adherence below the 
acceptable rate of 90%.  Lastly, subjects participating in the SAI were more likely to 
report adherence levels > 90%. 
 
Table 22 
Bivariate Analysis - Self-Reported Adherence: Sociodemographic and HIV Disease Specific 
Factors 
 
Covariates 
 
Self-Reported Adherence Pearson  
Chi-Square 
 (significance level .10 or less) 
> 90% 
 n       (%) 
<  90% 
n       (%) 
Sociodemographic Covariates 
Age (years) 
     19-29 
     30-39 
     40-49   
     50-59 
     > 60 
 
28 
83 
149 
86 
18 
 
(7.7) 
(22.8) 
(40.9) 
(23.6) 
(4.9) 
 
3 
11 
29 
12 
5 
 
(5.0) 
(18.3) 
(48.3) 
(20) 
(8.3) 
 
 
 
Gender   
     Male 
     Female 
 
259 
105 
 
(71.2) 
(28.8) 
 
40 
20 
 
(66.7) 
(33.3) 
 
Race  
    White 
     Black 
     Other 
 
199 
159 
6 
 
(54.7) 
(43.7) 
(1.6) 
 
30 
27 
3 
 
(50.0) 
(45.0) 
(5.0) 
 
Ethnicity 
     Non-Hispanic 
     Hispanic 
 
268 
96 
 
(73.6) 
(26.4) 
 
41 
19 
 
(68.3) 
(31.7) 
 
Income (% Federal Poverty Level) 
     <100 % 
     101-200 % 
     > 200 % 
 
244 
90 
30 
 
(67.0) 
(24.7) 
(8.2) 
 
48 
41 
1 
 
(80.0) 
(18.3) 
(1.7) 
 
Housing Status  
     Permanent 
     Nonpermanent 
 
359 
5 
 
(98.6) 
(1.4) 
 
57 
3 
 
(95.0) 
(5.0) 
 
Health Insurance 
     Yes 
     No 
 
239 
125 
 
(65.7) 
(34.3) 
 
49 
11 
 
(81.7) 
(18.3) 
 
6.059, df 1, p=.014 
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Table 22 continued 
Bivariate Analysis - Self-Reported Adherence: Sociodemographic and HIV Disease Specific 
Factors 
 
Covariates 
 
Self-Reported Adherence Pearson  
Chi-Square 
 (significance level .10 or less) 
> 90% 
 n       (%) 
<  90% 
n       (%) 
HIV Disease Specific Covariates 
HIV Risk Factor 
     MSM 
     Heterosexual 
     IDU 
     Other 
 
132 
197 
26 
9 
 
(36.3) 
(54.1) 
(7.1) 
(2.5) 
 
14 
36 
10 
0 
 
(23.3) 
(60.0) 
(16.7) 
(0) 
 
 
9.811, df 3, p=.020 
Disease Stage 
     HIV (non-AIDS) 
     AIDS 
 
138 
226 
 
(37.9) 
(62.1) 
 
17 
43 
 
(28.3) 
(71.7) 
 
 
 
 
 
      
      
Years Living with HIV 
     <5  
     6-10 
     11-15 
      >15 
 
149 
109 
69 
37 
 
(40.9) 
(29.9) 
(19.0) 
(10.2) 
 
28 
19 
8 
5 
 
(46.7) 
(31.7) 
(13.3) 
(8.3) 
 
Active Substance Abuse 
     Yes 
     No 
 
32 
332 
 
(8.8) 
(91.2) 
 
11 
49 
 
(18.3) 
(81.7) 
 
5.147, df 1, p=.023 
Mental Health Disorder 
     Yes 
     No 
 
96 
268 
 
(26.4) 
(73.6) 
 
23 
37 
 
(38.3) 
(61.7) 
 
3.649, df 1, p=.056 
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Table 23 
 
Bivariate Analysis- Self-Reported Adherence: ARV and Adherence Counseling and 
Intervention Specific Factors 
 
 
Covariates 
 
Self-Reported 
Adherence
Pearson  
Chi-Square 
(significance level .10 or less) > 90% 
 n       (%) 
<  90% 
n       (%) 
ARV Specific Covariates      
Dosing Frequency 
     Once Daily      
     Twice Daily 
 
113 
251 
 
(31.0) 
(69.0) 
 
19 
41 
 
(31.7) 
(68.3) 
 
Type of ARV Regimen 
     Protease Inhibitor 
     NNRTI 
     Triple NRTI 
 
199 
145 
20 
 
(54.7) 
(39.8) 
(5.5) 
 
36 
20 
4 
 
(60.0) 
(33.3) 
(6.7) 
 
Daily ARV Pill Burden 
     2-4 
     5-8 
     9-15 
 
151 
174 
39 
 
(41.5) 
(47.8) 
(10.7) 
 
22 
30 
8 
 
(36.7) 
(50.0) 
(13.3) 
 
Adherence Counseling and Intervention 
Received Adherence 
Counseling 
     Yes 
     No 
 
24 
340 
 
(6.6) 
(93.4) 
 
7 
53 
 
(11.7) 
(88.3) 
 
No. of Counseling Sessions 
     0 
     1 
     2 
     3 
     4 
     >5 
 
 
340 
18 
2 
2 
1 
1 
 
(93.4) 
(4.9) 
(0.5) 
(0.5) 
(0.3) 
(0.3) 
 
53 
5 
2 
0 
0 
0 
 
(88.3) 
(8.3) 
(3.3) 
(0) 
(0) 
(0) 
 
Adherence Counseling 
(minutes) 
     0 
     30-60 
     61-120 
     >120 
 
 
 340 
7 
13 
4 
  
 
(96.4) 
(1.9) 
(3.6) 
(1.1) 
 
 
53 
1 
3 
3 
 
 
(88.3) 
(1.7) 
(5.0) 
(5.0) 
 
Adherence Aids Prescribed 
     Yes 
     No 
 
13 
351 
 
(3.6) 
(96.4) 
 
3 
57 
 
(5.0) 
(95.0) 
 
Treatment Condition 
     SAI 
     Usual Care 
 
191 
173 
 
(52.5) 
(47.45) 
 
13 
47 
 
(21.7) 
(78.3) 
 
19.581, df 1, p<.0005 
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The initial factors included in the logistic regression included income, housing 
status, health insurance, HIV risk factor, active substance abuse, mental health disorder 
and treatment condition.  Through an iterative process factors that did not make 
significant contributions in the regression were removed and regression was repeated 
with the remaining factors.  Factors were reinserted if the model was negatively affected 
by the removal of a covariate.  Covariates selectively removed from the regression 
included income, health insurance, HIV risk factor, and mental health disorder.  Housing 
status was removed because a small sample size related to nonpermanently housed 
subjects created unstable results.   
After adjusting for covariates, subjects in the SAI group remained significantly 
more likely to self-report medication adherence > 90% as compared to the usual care 
group (adjusted OR = 3.944; 95% CI 2.058, 7.557; p < 0.0005).  Additionally, patients 
with a history of substance abuse were less likely to report favorable medication 
adherence (OR 2.237; CI 1.033, 4.864; p=.041).  Approximately 68% of all cases were 
explained by this regression model (c-statistic 0.677).   Based on the logistic regression 
results, the null hypothesis of no difference in self-reported adherence between the two 
groups was rejected.  Patients who participated in the SAI program were almost four 
times more likely to report adherence levels > 90%.  These results are presented in Table 
24.   
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Table 24 
Logistic Regression Analysis: Summary of Predictors of Self-Reported Adherence (> 90%) 
 
Variable 
 
β 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
Wald 
Chi- 
Square 
P 
Treatment Condition 1.372 3.944 2.058, 7.557 17.017 <.0005 
History of Substance Use -0.805 2.237 1.033, 4.864 4.167 0.041 
Note.  Overall model, Chi-Square = 24.566, df=2,  p <.0005.   
Pharmacy Refill Adherence 
Bivariate analyses were calculated on pharmacy refill adherence and each of the 
covariates and the treatment condition.  The data are displayed in Table 25.  There were 
several significant findings.  In most of the age groups, similar percentages of subjects 
had both favorable (> 90%) and unfavorable (<90%) pharmacy refill adherence.  
However, nearly twice as many subjects in the age range of 30-39 years had unfavorable 
pharmacy refill adherence (29.4%) while only 15.5% of subjects had favorable 
adherence.  An inverse relationship was seen in the age group of 50-59 years:  nearly 
double the percentage of subjects demonstrated favorable adherence (29.1%) while 
16.7% had unfavorable levels. These differences were significant (Chi-Square 17.287, df 
4, p=.002).  White patients also had a higher percentage of favorable pharmacy refill 
adherence.  
A higher percentage of subjects with household income <100% of Federal 
Poverty Level demonstrated lower adherence levels (76% compared with 62.3%) while 
those with income levels between 101-200% had nearly twice the rate of favorable 
pharmacy refill adherence at a level > 90% (29.5% compared to 17.6%).  A greater 
percentage of subjects without health insurance (38.2%) demonstrated pharmacy refill 
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adherence > 90% compared with insured patients (25.5%) (Chi-Square 7.862, df 1, 
p=.005).  Of subjects reporting active substance use, almost twice as many demonstrated 
pharmacy refill adherence <90% (13.2%) compared to those with favorable refill 
adherence (7.3%).    
 
Table 25 
Bivariate Analysis- Pharmacy Refill Adherence: Sociodemographic and HIV Disease 
Specific Factors 
 
Covariates 
 
Pharmacy Refill Adherence Pearson  
Chi-Square 
(significance level .10 or less) 
> 90% 
n=204 
 n       (%) 
<  90% 
n=220 
n       (%) 
Sociodemographic Covariates 
Age (years) 
     18-29 
     30-39 
     40-49   
     50-59 
     > 60 
 
14 
34 
95 
64 
13 
 
(6.4) 
(15.5) 
(43.2) 
(29.1) 
(5.9) 
 
17 
60 
83 
34 
10 
 
(8.3) 
(29.4) 
(40.7) 
(16.7) 
(4.9) 
 
 
 
17.287, df 4, p=.002 
Gender   
     Male 
     Female 
 
160 
60 
 
(72.7) 
(27.3) 
 
139 
65 
 
(68.1) 
(31.9) 
 
Race  
    White 
     Black 
     Other 
 
137 
77 
6 
 
(62.3) 
(35.0) 
(2.7) 
 
92 
109 
3 
 
(45.1) 
(53.4) 
(1.5) 
 
 
14.765, df 2, p=.001 
Ethnicity 
     Non-Hispanic 
     Hispanic 
 
155 
65 
 
(70.5) 
(29.5) 
 
154 
50 
 
(75.5) 
(24.5) 
 
Income  (% Federal Poverty Level) 
     <100 % 
     101-200 % 
     > 200 % 
 
137 
65 
18 
 
(62.3) 
(29.5) 
(8.2) 
 
155 
36 
13 
 
(76.0) 
(17.6) 
(6.4) 
 
 
9.653, df 2, p=.008 
Housing Status  
     Permanent 
     Nonpermanent 
 
215 
5 
 
(97.7) 
(2.3) 
 
201 
3 
 
(98.5) 
(1.5) 
 
Health Insurance 
     Yes 
     No 
 
136 
84 
 
(61.8) 
(38.2) 
 
152 
52 
 
(74.5) 
(25.5) 
 
7.862, df 1, p=.005 
 
   
 
 
 
102
Table 25 continued 
Bivariate Analysis- Pharmacy Refill Adherence: Sociodemographic and HIV Disease 
Specific Factors 
 
Covariates 
 
Pharmacy Refill Adherence Pearson  
Chi-Square 
(significance level .10 or less) 
> 90% 
n=204 
 n       (%) 
<  90% 
n=220 
n       (%) 
HIV Disease Specific Factors covariates 
HIV Risk Factor 
     MSM 
     Heterosexual 
     IDU 
     Other 
 
88 
111 
18 
3 
 
(40.0) 
(50.5) 
(8.2) 
(1.4) 
 
58 
122 
18 
6 
 
(28.4) 
(59.8) 
(8.8) 
(2.9) 
 
 
7.09, df 3, p=.069 
Disease Stage 
     HIV (non-AIDS) 
     AIDS 
 
90 
130 
 
(40.9) 
(50.1) 
 
65 
139 
 
(31.9) 
(68.1) 
 
3.735, df 1, p=.053 
Years Living with HIV 
     <5  
     6-10 
     11-15 
      >15 
 
96 
73 
32 
19 
 
(43.6) 
(33.2) 
(14.5) 
(8.6) 
 
81 
55 
45 
23 
 
(39.7) 
(27.0) 
(21.1) 
(11.3) 
 
Active Substance Abuse 
     Yes 
     No 
 
16 
204 
 
(7.3) 
(92.7) 
 
27 
177 
 
(13.2) 
(86.8) 
 
4.129, df 1, p=.042 
Mental Health Disorder 
     Yes 
     No 
 
63 
157 
 
(52.9) 
(51.5) 
 
56 
148 
 
(47.1) 
(48.5) 
 
 
There were no significant differences between pharmacy refill adherence and 
ARV characteristics and adherence counseling and intervention specific factors.  Lastly, a 
higher percentage (54.5%) of subjects participating in the SAI had pharmacy refill 
adherence > 90% compared to those receiving usual care (45.5%) (Chi-square 0.578, df 1, 
p=.008).   These data are displayed in Table 26. 
The initial factors included in the logistic regression for pharmacy refill adherence 
included age, race, income, health insurance, HIV risk factor, disease stage, active 
substance abuse, time associated with adherence counseling and treatment condition. 
Factors that did not have significant contributions in the regression were removed 
including time associated with adherence counseling, and active substance abuse.  Health 
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insurance was removed as it was believed that this factor and the treatment condition of 
SAI explained the same information. 
 
Table 26 
 
Bivariate Analysis - Pharmacy Refill Adherence: ARV and Adherence Counseling and 
Intervention Specific Factors 
 
 
Covariates 
 
Pharmacy Refill Adherence Pearson  
Chi-Square 
(significance level .10 or less) 
> 90% 
 n       (%) 
<  90% 
n       (%) 
ARV Covariates 
Dosing Frequency 
     Once Daily      
     Twice Daily 
 
65 
155 
 
(29.5) 
(70.5) 
 
67 
137 
 
(32.8) 
(67.2) 
 
Type of ARV Regimen 
     Protease Inhibitor 
     NNRTI 
     Triple NRTI 
 
115 
92 
13 
 
(52.3) 
(41.8) 
(5.9) 
 
120 
73 
11 
 
(58.8) 
(35.8) 
(5.4) 
 
Daily ARV Pill Burden 
     2-4 
     5-8 
     9-15 
 
95 
104 
21 
 
(43.2) 
(47.3) 
(9.5) 
 
78 
100 
26 
 
(38.2) 
(49.0) 
(12.7) 
 
Adherence Services and Intervention 
Received Adherence 
Counseling 
     Yes 
     No 
 
 
12 
208 
 
 
(5.5) 
(94.5) 
 
 
19 
185 
 
 
(9.3) 
(90.7) 
 
No. of Counseling Sessions 
     0 
     1 
     2 
     3 
     4 
     >5 
 
208 
10 
2 
0 
0 
0 
 
(94.5) 
(4.5) 
(0.9) 
(0) 
(0) 
(0) 
 
185 
13 
2 
2 
1 
1 
 
(90.7) 
(6.4) 
(1.0) 
(1.0) 
(0.5) 
(0.5) 
 
Adherence Counseling 
(minutes) 
     0 
     30-60 
     61-120 
     >120 
 
 
208 
2 
9 
1 
 
 
(94.5) 
(0.9) 
(4.1) 
(0.5) 
 
 
185 
6 
7 
6 
 
 
(90.7) 
(2.9)  
(3.4) 
(2.9) 
 
 
 
Adherence Aids Prescribed 
     Yes 
     No 
 
6 
214 
 
(2.7) 
(97.3) 
 
10 
194 
 
(4.9) 
(95.1) 
 
Treatment Condition 
     SAI 
     Usual Care 
 
120 
100 
 
(54.5) 
(45.5) 
 
84 
120 
 
(41.2) 
(58.8) 
 
7.578, df 1, p=.006 
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After adjusting for covariates, subjects in the SAI group remained significantly 
more likely to achieve 90% or more pharmacy refill adherence compared to the usual 
care group (OR 1.833, CI 1.206, 2.788; p=.005).  In this regression, age was treated as a 
continuous variable.  For every increase in year of age, there was approximately a 5% 
increase in the likelihood of having a favorable pharmacy refill adherence outcome.  
White race had a negative association with pharmacy refill adherence (OR 0.496; CI 
.039, 0.749; p=.001).   Approximately 68% of all cases were correctly predicted by this 
regression model (c-statistic 0.683).  Based on the logistic regression results, the null 
hypothesis for hypothesis number two was rejected.  These results are presented in Table 
27. 
 
Table 27 
Logistic Regression Analysis: Summary of Predictors of Pharmacy Refill Adherence 
 
Variable 
 
β 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
Wald 
Chi- 
Square 
P 
Treatment Condition 0.606 1.833 1.206 – 2.788 8.038 0.005 
Age 0.049 1.050 1.026 – 1.074  17.633 <.0005 
Race -0.701 0.496 0.329 – 0.749 11.150 0.001 
Note.  Overall model, Chi-Square = 43.012, df=5,  p < .0005.    
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Study Aim One: Summary 
The two hypotheses associated with the first study aim were supported.   Logistic 
regression analyses support significant differences in self-reported adherence and pharmacy 
refill adherence associated with participation in the SAI program. 
Study Aim Two: Treatment Response Outcomes 
 The purpose of the second study aim was to determine whether patients participating 
in the SAI program experience improved response to treatment compared to patients 
receiving usual care, controlling for HIV disease-specific factors, ARV-specific factors, and 
sociodemographic factors. Two hypotheses were tested:  
1) Patients participating in the SAI program will have better immunologic (CD4 
lymphocyte) responses to HAART compared to patients receiving usual care, 
controlling for selected covariates. 
2) Patients participating in the SAI program will have better virologic (HIV RNA) 
responses compared to patients receiving usual care, controlling for selected 
covariates. 
CD4 Lymphocyte Response 
There were few statistically significant findings in the bivariate analyses of CD4 
lymphocyte response and each of the covariates and the treatment condition.  Overall, 
approximately 64% of subjects in this study demonstrated an unfavorable declining CD4 
lymphocyte response.  Although the difference is not significant, a larger percentage of 
subjects identifying as Hispanic had a declining CD4 response (57.4% compared with 33.7% 
for non-Hispanic) (Chi-square 2.912, df 1, p=.088).   All 8 of the subjects with non-
permanent housing demonstrated a stable or increasing CD4 response (Chi square 3.147, df 1, 
p=.076, Yates’ Correction for Continuity).  This information is displayed in Table 28. 
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Table 28 
Bivariate Analysis - CD4 Lymphocyte Response: Sociodemographic and HIV Disease 
Specific Factors 
 
Covariates 
 
CD4 Lymphocyte Pearson  
Chi-Square 
(significance level .10 or less) 
Declining 
      N          (%) 
Stable/Increasing 
n       (%) 
Sociodemographic Covariates 
Age (years) 
     19-29 
     30-39 
     40-49   
     50-59 
     > 60 
 
13 
35 
58 
36 
11 
 
(8.5) 
(22.9) 
(37.9) 
(23.5) 
(7.2) 
 
18 
59 
120 
62 
12 
 
(6.6) 
(21.8 
(44.3) 
(22.9) 
(4.4) 
 
 
 
Gender   
     Male 
     Female 
 
112 
41 
 
(73.2) 
(26.8) 
 
187 
84 
 
(69.0) 
(31.0) 
 
Race  
    White 
     Black 
     Other 
 
78 
71 
4 
 
(51.0) 
(46.4) 
(2.6) 
 
151 
115 
5 
 
(55.7) 
(42.4) 
(1.8) 
 
Ethnicity 
     Non-Hispanic 
     Hispanic 
 
104 
49 
 
(68.0) 
(32.0) 
 
205 
66 
 
(75.6) 
(24.4) 
 
2.912, df 1 p=.088 
Income 
 (% Federal Poverty Level) 
     <100 % 
     101-200 % 
     > 200 % 
 
 
113 
30 
10 
 
 
(73.9) 
(19.6) 
(6.5) 
 
 
179 
71 
21 
 
 
(66.1) 
(26.2) 
(7.7) 
 
Housing Status  
       Nonpermanent 
       Permanent 
 
0 
153 
b 
(0) 
(100) 
 
8 
263 
g 
(3.0) 
(97.0) 
 
3.147, df 1, p=.076  
(Yates’ Correction for Continuity) 
Health Insurance 
     Yes 
     No 
 
46 
107 
 
(30.1) 
(69.9) 
 
90 
180 
 
(33.2) 
(66.8) 
 
HIV Disease Specific Factors 
HIV Risk Factor 
     MSM 
     Heterosexual 
     IDU 
     Other 
 
52 
82 
16 
3 
 
(34.0) 
(53.6) 
(10.5) 
(2.0) 
 
94 
151 
20 
6 
 
(34.7) 
(55.7) 
(7.4) 
(2.2) 
 
Disease Stage 
     HIV (non-AIDS) 
     AIDS 
 
59 
94 
 
(38.6) 
(61.4) 
 
96 
175 
 
(35.4) 
(64.6) 
 
 
Years Living with HIV 
     <5  
     6-10 
     11-15 
      >15 
 
61 
43 
33 
16 
 
(39.9) 
(28.1) 
(21.6) 
(10.5) 
 
116 
85 
44 
26 
 
(42.8) 
(31.4) 
(16.2) 
(9.6) 
 
Active Substance Abuse 
     Yes 
     No 
 
19 
134 
 
 (12.4) 
(87.6) 
 
24 
247 
 
(8.9) 
(91.9) 
 
Mental Health Disorder 
     Yes 
     No 
 
46 
107 
 
(30.1) 
(69.9) 
 
73 
198 
 
(26.9) 
(73.1) 
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 Of the 271 subjects with a favorable CD4 response, 34.3% received a once daily 
regimen while 65.7% received a twice daily regimen (Chi-square 3.554, df 1, p=.059).  
Immunologic response based on pill burden was similar when subjects received 2-4 or 5-
8 pills per day.  However, when daily pill burden exceeded 8 pills per day, there were a 
higher percentage of subjects that had CD4 decline (Chi-square 8.719, df 2, p=.013).  
Lastly, 68% of subjects in the SAI (n=139) had a favorable immunologic response 
compared with only 60% of those in usual care (n=132) (Chi-square 3.039 df 1, p=.0816).  
Table 29 depicts this information. 
 
Table 29 
Bivariate Analysis- CD4 Lymphocyte Response: ARV and Adherence Counseling and 
Intervention Specific Factors 
 
Covariates 
 
CD4 Lymphocyte Pearson  
Chi-Square 
(significance level .10 or less) 
Declining 
      n          (%) 
Stable/Increasing 
n       (%) 
ARV Specific Covariates 
Dosing Frequency 
     Once Daily      
     Twice Daily 
 
39 
114 
 
(25.5) 
(74.5) 
 
93 
178 
 
(34.3) 
(65.7) 
 
3.554, df 1, p=.059 
Type of ARV Regimen 
     Protease Inhibitor 
     NNRTI 
     Triple NRTI 
 
89 
56 
8 
 
(58.2) 
(36.6) 
(5.2) 
 
146 
109 
16 
 
(53.0) 
(40.2) 
(5.9) 
 
Daily ARV Pill Burden 
     2-4 
     5-8 
     9-15 
 
56 
71 
26 
 
(36.6) 
(46.4) 
(17.0) 
 
117 
133 
21 
 
(43.2) 
(49.1) 
(7.7) 
 
 
8.719, df 2, p=.013 
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Table 29 continued 
Bivariate Analysis- CD4 Lymphocyte Response: ARV and Adherence Counseling and 
Intervention Specific Factors 
 
Covariates 
 
CD4 Lymphocyte Pearson  
Chi-Square 
(significance level .10 or less) 
Declining 
      n          (%) 
Stable/Increasing 
n       (%) 
Adherence Services and Intervention 
Received Adherence 
Counseling 
     Yes 
     No 
 
 
10 
143 
 
 
(6.5) 
(93.5) 
 
 
21 
250 
 
 
(7.7) 
(92.3) 
 
No. of Counseling Sessions 
     0 
     1 
     2 
     3 
     4 
     >5 
 
143 
10 
0 
0 
0 
0 
 
(93.5) 
(6.5) 
(0) 
(0) 
(0) 
(0) 
 
250 
13 
4 
2 
1 
1 
 
(92.3) 
(4.8) 
(150) 
(0.7) 
(0.6) 
(0.6) 
 
Adherence Counseling 
(minutes) 
     0 
     30-60 
     61-120 
     >120 
 
 
143 
5 
4 
1 
 
 
(93.5) 
(3.3) 
(2.6) 
(0.7) 
 
 
250 
3 
12 
6 
 
 
(92.3) 
(1.1)  
(4.4) 
(2.2) 
 
 
Adherence Aids Prescribed 
     Yes 
     No 
 
3 
150 
 
(2.0) 
(98.0) 
 
13 
258 
 
(4.8) 
(95.2) 
 
Treatment Condition 
     SAI 
     Usual Care 
 
65 
88 
 
(42.5) 
(57.5) 
 
139 
132 
 
(51.3) 
(48.7) 
 
3.039 df 1, p=.0816 
 
 
 
The initial factors included in the regression for CD4 lymphocyte response 
included ethnicity, housing status, ARV dosing, ARV daily pill burden, and treatment 
condition.  Factors that did not have significant contributions in the regression were 
removed (housing status and ARV dosing) and regression was repeated with the 
remaining factors.  The only significant finding in this regression was related to daily pill 
burden.  Subjects receiving 2-4 tablets per day were less likely to achieve a favorable 
CD4 lymphocyte response (OR  0.917; CI 0.844, 0.996; p=.039).  Approximately 59% of 
all cases were correctly predicted by this regression model (c-statistic 0.594).  Based on 
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logistic regression analysis, the null hypothesis for the third research question was 
supported as no significant relationship was identified between the SAI program and CD4 
lymphocyte response. These results are presented in Table 30. 
 
Table 30 
Logistic Regression Analysis: Summary of Predictors of CD4 Lymphocyte Response 
 
Variable 
 
β 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
Wald 
Chi- 
Square 
P 
Ethnicity 0.392 1.480 0.949 – 2.306 2.996 0.083 
Daily Pill Burden -.087 0.917 0.844 – 0.996 4.287 0.039 
Treatment Condition 0.338 1.402 0.935 – 2.102 2.670 0.102 
Note.  Overall model, Chi-Square = 10.535, df=3,  p = .015.    
 
HIV RNA Response 
There were a number of statistically significant findings in the bivariate analyses 
of HIV RNA response, the covariates and the treatment condition.  The 
sociodemographic and HIV disease specific data are displayed in Table 31.   
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Table 31 
Bivariate Analysis- HIV RNA Response: Sociodemographic and HIV Disease Specific 
Factors 
 
Covariates 
 
HIV RNA Response Pearson  
Chi-Square 
(significance level .10 or less) 
Increasing 
      n          (%) 
Stable/Decreasing 
n       (%) 
Sociodemographic Covariates 
Age (years) 
     19-29 
     30-39 
     40-49   
     50-59 
     > 60 
 
9 
32 
74 
34 
12 
 
(5.6) 
(19.9) 
(46.0) 
(21.1) 
(7.5) 
 
22 
62 
104 
64 
11 
 
(8.4) 
(23.6 
(39.5) 
(24.3) 
(4.2) 
 
 
 
Gender   
     Male 
     Female 
 
113 
48 
 
(70.2) 
(29.8) 
 
186 
77 
 
(70.7) 
(29.3) 
 
Race  
    White 
     Black 
     Other 
 
74 
83 
4 
 
(46.0) 
(51.6) 
(2.5) 
 
155 
103 
5 
 
(58.9) 
(39.2) 
(1.9) 
 
 
6.766, df 2,  p=.034 
Ethnicity 
     Non-Hispanic 
     Hispanic 
 
122 
39 
 
(75.8) 
(24.2) 
 
187 
76 
 
(71.1) 
(28.9) 
 
Income 
 (% Federal Poverty 
Level) 
     <100 % 
     101-200 % 
     > 200 % 
 
 
117 
28 
6 
 
 
(72.7) 
(23.6) 
(3.7) 
 
 
175 
63 
25 
 
 
(66.5) 
(24.0) 
(9.5) 
 
 
5.112, df 2, p=.078 
Housing Status  
     Permanent 
     Nonpermanent 
 
157 
4 
 
 (97.5) 
(2.5) 
 
259 
4 
 
(98.5) 
(1.5) 
 
Health Insurance 
     Yes 
     No 
 
135 
26 
 
(83.9) 
(16.1) 
 
153 
110 
 
(58.2) 
(41.8) 
 
30.218, df 1 p<.0005 
HIV Disease Specific Covariates 
HIV Risk Factor 
     MSM 
     Heterosexual 
     IDU 
     Other 
 
53 
88 
15 
5 
 
(32.9) 
(54.7) 
(9.3) 
(3.4) 
 
93 
145 
21 
4 
 
(35.4 
(55.1) 
(8.0) 
(1.5) 
 
Disease Stage 
     HIV (non-AIDS) 
     AIDS 
 
50 
111 
 
(31.1) 
(68.9) 
 
105 
158 
 
(39.9) 
(60.1) 
 
3.386, df 1, p=.066 
Years Living with HIV 
     <5  
     6-10 
     11-15 
      >15 
 
62 
52 
32 
15 
 
(38.5) 
(32.3) 
(19.9) 
(9.3) 
 
115 
76 
45 
27 
 
(43.7) 
(28.9) 
(17.1) 
(10.3 
 
Active Substance Abuse 
     Yes 
     No 
 
19 
142 
 
(11.8) 
(88.2) 
 
24 
239 
 
(9.1) 
(90.9) 
 
Mental Health Disorder 
     Yes 
     No 
 
47 
114 
 
(29.2) 
(70.8) 
 
72 
191 
 
(27.4) 
(72.6 
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 Bivariate analysis suggested there were racial differences related to virologic 
response. A higher percentage of white patients achieved or sustained a virologic 
response (58.9%) compared to blacks (39.2%) (Chi-square 6.766, df 2,  p=.034).  A 
higher percentage of subjects in the lowest income group experienced increasing HIV 
RNA while a greater percentage of patients at the highest income level of >200% FPL 
had a favorable virologic response (Chi-square 5.112, df 2, p=.078).   
Sixty-two percent of all subjects had a favorable virologic response (n=263).  Of 
these, 58.2% had insurance, 41.8% did not.  Of the 161 subjects that had unfavorable 
virologic responses, 16.1% did not have insurance while 83.9% did have insurance (Chi 
square 30.218, df 1 p<.0005). 
Almost two-thirds of the patients had a diagnosis of AIDS.  Of patients with an 
unfavorable HIV RNA response, 68.9% had an AIDS diagnosis.  Of the 163 subjects that 
had a favorable HIV RNA response, 60.1% had an AIDS diagnosis. 
Although few patients received adherence aids (n=16), 87.5% of them were 
prescribed to subjects that demonstrated stable or declining HIV RNA (Chi-square 4.58, 
df 1, p=.032).  Lastly, 61.6% of subjects participating in the SAI demonstrated favorable 
virologic responses compared to 38.4% of those in usual care (Chi-square 50.442, df 1, 
p<.0005).  This data is presented in Table 32. 
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 Table 32 
 
Bivariate Analysis- HIV RNA Response: ARV and Adherence Counseling and 
Intervention Specific Factors 
 
 
Covariates 
 
CD4 Lymphocyte Pearson  
Chi-Square 
(significance level .10 or less) 
Declining 
      n          (%) 
Stable/Increasing 
n       (%)) 
ARV Specific Covariates 
Dosing Frequency 
     Once Daily      
     Twice Daily 
 
49 
112 
 
(30.4) 
(69.6) 
 
83 
180 
 
(31.6) 
(68.4) 
 
 
Type of ARV Regimen 
     Protease Inhibitor 
     NNRTI 
     Triple NRTI 
 
89 
65 
7 
 
(55.3) 
(40.4) 
(9.1) 
 
146 
100 
17 
 
(55.5) 
(38.0) 
(6.5) 
 
 
Daily ARV Pill Burden 
     2-4 
     5-8 
     9-15 
 
61 
76 
24 
 
(37.9) 
(47.2) 
(14.9) 
 
112 
128 
23 
 
(42.6) 
(48.7) 
(8.7) 
 
Adherence Services and Intervention 
Received Adherence 
Counseling 
     Yes 
     No 
 
 
8 
153 
 
 
(5.0) 
(95.0) 
 
 
23 
240 
 
 
(8.7) 
(91.3) 
 
No. of Counseling Sessions 
     0 
     1 
     2 
     3 
     4 
     >5 
 
153 
8 
0 
0 
0 
0 
 
(95.0) 
(5.0) 
(0) 
(0) 
(0) 
(0) 
 
240 
15 
4 
2 
1 
1 
 
(91.3) 
(5.7) 
(1.5) 
(0.8) 
(0.4) 
(0.4) 
 
Adherence Counseling 
(minutes) 
     0 
     30-60 
     61-120 
     >120 
 
 
153 
4 
4 
0 
 
 
(95.0) 
(2.5) 
(2.5) 
(0) 
 
 
240 
4 
12 
7 
 
 
(91.3) 
(1.5)  
(4.6) 
(2.7) 
 
 
Adherence Aids Prescribed 
     Yes 
     No 
 
2 
159 
 
(1.2) 
(98.8) 
 
14 
249 
 
(5.3) 
(94.7) 
 
4.58, df 1, p=.032 
Treatment Condition 
     SAI 
     Usual Care 
 
42 
119 
 
(26.1) 
(73.9) 
 
162 
101 
 
(61.6) 
(38.4) 
 
50.442, df 1, p<.0005 
 
The initial factors included in the regression for HIV RNA response included 
race, income, health insurance, HIV disease stage, adherence aids prescribed and 
treatment condition.  Factors that did not have significant contributions in the regression 
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were removed (race, health insurance and income) and regression was repeated with the 
remaining factors.  After adjusting for covariates, subjects who participated in the SAI 
program were over four and a half times more likely to achieve a favorable virologic 
response (OR 4.573; CI 2.953, 7.080; p<.0005).  Subjects who received an adherence aid 
were almost seven times more likely to achieve a favorable VL response (OR 6.87; CI 
1.473, 32.072; p=.014).  Approximately 73% of all cases were correctly predicted by this 
regression model (c-statistic 0.725).  Based on this logistic regression, the null hypothesis 
of no differences in virologic response between the SAI and usual care group for 
hypothesis number four was rejected.   These results are presented in Table 33.   
 
Table 33 
Logistic Regression Analysis: Summary of Predictors of HIV RNA Response 
 
Variable 
 
β 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
Wald 
Chi- 
Square 
 
p 
Treatment Condition 1.520 4.573 2.953 - 7.080 46.411 <.0005 
Race 0.465 1.592 1.039 - 2.438 4.564 0.033 
Adherence Aids 1.928 6.873 1.473 - 32.072 6.015 0.014 
Note.  Overall model, Chi-Square = 63.999, df=3,  p <.0005.    
 
Study Aim Two: Summary 
 The first hypothesis associated with study aim two was rejected as there were no 
significant differences in CD4 lymphocyte response between the SAI and usual care 
group.  The second hypotheses was supported as logistic regression analyses 
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demonstrated significant differences in HIV RNA response associated with the SAI 
program. 
Summary 
 This chapter has presented the statistical analyses for the investigation.  
Demographic results were presented first, followed by the results of bivariate analyses 
between the adherence outcomes, treatment outcomes, treatment groups and covariates.  
Finally, the results of the logistic regression for each study aim were presented.  Three 
hypotheses were supported; one was rejected. In the concluding chapter, these results will 
be discussed along with a discussion of the implications for future research and nursing 
practice. 
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CHAPTER 5: DISCUSSSION, CONCLUSIONS AND RECOMMENDATIONS 
Introduction 
 This final chapter presents a synthesis of the research results with a discussion of 
the findings, conclusions, study limitations and implications for clinical practice.   
Recommendations for dissemination of the findings and for future research are proposed. 
Summary of the Study 
The purpose of this retrospective comparative study was to better understand the 
effects of an existing antiretroviral access program on adherence to HAART and response 
to treatment compared to patients enrolled in usual care. In the structured adherence 
intervention (SAI) staff closely monitored monthly HIV medication refills and provided 
structured adherence interventions when indicated.  Patients receiving usual care were 
enrolled in a Medicaid-funded medication access program and did not receive ongoing 
medication refill monitoring and structured adherence intervention.  Both patient groups 
received their ARV medications and outpatient HIV medical care from a single treatment 
center and pharmacy. 
The study included 424 subjects comparably distributed between the usual care 
and SAI group.  Bivariate analyses were used to identify significant associations between 
the usual care and SAI group regarding sociodemographic characteristics, HIV disease 
related factors, ARV-related characteristics and utilization of adherence services and 
intervention.  Logistic regression was performed to identify predictors of self-reported 
medication adherence, pharmacy refill adherence, CD4 lymphocyte response and HIV 
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RNA response.  This research provided valuable information related to antiretroviral 
adherence and treatment outcomes for patients participating in usual care and a state-
based antiretroviral access program. The study is unique in that no known investigations 
have previously tested a structured programmatic intervention on ARV adherence and 
HIV treatment outcomes. 
Discussion and Conclusions 
The following is a discussion of the findings according to the study aims and 
research questions in the study along with the conclusions that may be drawn from this 
research study.   
Study Aim One 
The first study aim was to determine whether patients participating in the SAI 
program experienced higher levels of adherence compared to patients receiving usual 
care, controlling for adherence services and intervention, HIV disease-specific factors, 
ARV-specific factors, and sociodemographic factors. To answer the first research 
question, “Is there a difference in self-reported adherence in subjects participating in the 
SAI program compared to those who receive usual care?,” logistic regression was 
performed to test the null hypotheses that there were no differences between self-reported 
adherence between participants in the usual care group of subjects and the subjects 
participating in the SAI.  After controlling for covariates, subjects in the SAI group were 
significantly more likely to self-report medication adherence > 90% as compared to the 
usual care group (OR = 3.944; 95% CI 2.058, 7.557; p < 0.0005) and the null hypothesis 
was rejected. 
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To answer the second research question, “Is there a difference in pharmacy refill 
adherence in subjects participating in the SAI program compared to those who receive 
usual care?,” logistic regression was performed to test the null hypothesis that there were 
no differences between pharmacy refill adherence between participants in the usual care 
group of subjects and the subjects participating in the SAI.  After adjusting for covariates, 
subjects in the SAI group remained significantly more likely to achieve 90% or more 
pharmacy refill adherence compared to the usual care group (OR 1.833, 95% CI 1.206, 
2.788;  p=.005). The null hypothesis was rejected.  
Several unexpected findings were seen in this study including low overall 
utilization of the adherence specialist and comparable use of the adherence specialist 
between the two study groups.  The majority of the study population (92.7%) did not 
receive any adherence counseling or intervention (n=393) from the adherence specialist.  
A total of only 31 subjects (7.3%) received at least one face-to-face counseling session 
with the adherence specialist.   The range of counseling time was 30-360 minutes with a 
mean of 91 minutes during the 6 month study period.  Fewer than 4% of all patients 
received adherence aids such as pill boxes, customized medication schedules, and alarm 
watches (n=16) from the adherence specialist.   
There are several potential explanations for the unexpected low utilization of the 
adherence specialist’s services.  Primary healthcare providers (PCPs) delivering 
outpatient care services to the subjects may have provided adherence interventions on 
their own without initiating formal consultation with the adherence specialist.  Similarly, 
PCPs may have initiated the use of pill boxes and may have developed detailed written 
medication schedules without the involvement and knowledge of the adherence 
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specialist.  If these interventions were provided by the PCP, they would not have been 
captured by the databases used in this study.  Patients may also have received adherence 
education and counseling services from community case management organizations that 
receive Ryan White Grant funding specifically for these purposes.  Similarly, these 
interventions could not have been measured and included in this study. 
Based on the embedded procedural and administrative processes associated with 
the ADAP, it seemed likely that clients in this program would demonstrate greater 
utilization of adherence services and intervention then the usual care group.  In this study, 
utilization of adherence services between the two groups was comparable.  It is possible 
that PCPs and other staff were accustomed to providing adherence support to patients in 
the SAI group and consequently extended these interventions to all patients as a 
component of routine care.  Healthcare providers may have had little knowledge of the 
patients’ method of medication access and consequently delivered comparable services to 
all patients within the normal course of health care delivery. 
Surprisingly, there were no significant differences in pharmacy refill adherence, 
self-reported adherence, and HIV RNA response related to ARV pill burden. While the 
literature supports improved adherence with lower pill burden, this study showed 
comparable adherence and treatment outcomes regardless of ARV pill burden.  The 
largest percentage of subjects (48.1%) had a pill burden of 5-8 ARV pills per day while 
only 11.1% had daily pill burden of 9-15 and 43.2% received 2-4 per day.  Although 
immunologic response based on pill burden was similar whether subjects received 2-4 or 
5-8 pills per day, a higher percentage of subjects experienced CD4 decline when daily 
pill burden exceeded 8 pills (Chi-square 8.719, df 2, p=.013).   
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Pill burden for treatment of other health disorders such as diabetes, psychiatric 
conditions, cardiovascular and metabolic disorders was not assessed in this study.  It is 
possible that HAART bill burden was minimal compared to pill burden associated with 
the treatment of other health conditions.  Measurement of overall pill burden may better 
explain any potential differences in adherence and treatment outcomes.    
Study Aim Two 
The second study aim was to determine whether patients participating in the SAI 
program experienced improved response to treatment compared to patients receiving 
usual care, controlling for HIV disease-specific factors, ARV-specific factors, and socio-
demographic factors.   
To answer the first research question, “Is there a difference in CD4 lymphocyte 
response in subjects participating in the SAI program compared to those who receive 
usual care?” logistic regression was performed to test the null hypotheses that there were 
no differences between CD4 lymphocyte response in the usual care group of subjects and 
the subjects participating in the SAI.  After controlling for covariates, there were no 
significant differences between the two groups and the null hypothesis was supported  
(OR 1.402; CI: 1.402,2.102; p = 0.102). 
This unexpected finding may be explained by several factors.  Most notably, 
expected CD4 lymphocyte response occurs more slowly compared to HIV RNA response 
which occurs more rapidly when initiating ARV therapy (Bartlett & Gallant, 2005; 
Nieuwkerk & Oort, 2005).  It is likely that a six-month observation period may have been 
inadequate to fully appreciate the immunologic response to therapy.  CD4 lymphocytes 
are also affected by diurnal and seasonal variations.  Some clinicians prefer to monitor 
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the percentage of CD4 lymphocytes rather than the absolute number (Bartlett & Gallant, 
2005), but not all laboratories provide this additional measurement.  Unfortunately CD4 
percentages were not available in this study.  The subjects in this study also included a 
broad mix of clients at all ranges of HIV disease.  Patients starting initial therapy would 
be expected to have a robust CD4 lymphocyte response while it would be unlikely for 
those chronically infected and on long-term therapy to experience a significant response.  
Lastly, the sample size was lower than expected and there may not have been enough 
power associated with this sample size to detect a small change in the CD4 lymphocyte 
response. 
To answer the final research question, “Is there a difference in HIV RNA 
response in subjects participating in the SAI program compared to those who receive 
usual care?” logistic regression was performed to test the null hypotheses that there were 
no differences in the HIV RNA response between the two groups. After controlling for 
covariates, subjects who participated in the SAI program were over four and a half times 
more likely to achieve a favorable virologic response (OR 4.573; 95% CI 2.953, 7.080; 
p<.0005).  There was a statistically significant difference between the two groups and the 
null hypothesis of no difference between the groups was rejected.  
Limitations of the Study 
 There are several limitations to consider in this study. Each of these will be 
reviewed in the following section.   
 The sample was biased because all subjects were already enrolled in an AIDS 
drug assistance program and they all received care from one outpatient clinic.  
Additionally, all subjects received medication from one pharmacy.  Clinical, pharmacy 
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and medication access programs were all at the same site.   As a result, the findings may 
not be representative of the true population in the state-wide ADAP.  The sample did 
represent racial and ethnic diversity consistent with HIV-infected patients within the local 
community. 
Another source of bias is related to self-reported measurement of adherence.  
Although self-report is one of the most common methods of assessing medication 
adherence, inaccuracy may result due to imprecise or inconsistent questioning, patient 
forgetfulness and poor recall, or the patient’s desire to provide socially desirable 
responses along with a desire to please the healthcare provider and prevent criticism.   
Consequently, when self-reporting methods are used to assess adherence, levels are 
frequently over-estimated.  
The retrospective research design was purposely selected to minimize several 
possible confounders that existed in the years 2006 and 2007.  Medicare D prescription 
drug plans were initiated in January 2006.  Clients experienced unique barriers to 
medication access, unexpected loss of previous healthcare benefits and interruptions in 
their supply of medication. While most of the Medicare D complications resolved by 
2007, eligibility requirements for Florida ADAP and other local funding plans occurred 
in 2007, once again disrupting the normal operations of ADAP. 
A priori power estimates suggested a minimum sample size of 678 subjects were 
required for power of 0.80.  A large number of potential subjects were unexpectedly 
excluded from analysis because they did not use the on-site pharmacy.  Consequently, 
this study is inadequately powered to detect the effect size specified in the research 
design. 
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The findings of this research may not be generalizable to other populations.  The 
sample of the participants may not reflect the overall population of those with HIV since 
the study site was a public clinic frequently used by those who are indigent or have public 
insurance such as Medicare or Medicaid.  Patients with commercial insurance tend to 
seek private practices for their HIV care, so those employed in jobs that provide 
insurance were underrepresented in this sample, as well as those with high income.     
These findings cannot be applied to populations that were not represented in the subject 
groups.    Further studies are recommended across various geographic areas, ethnic areas 
and other clinical settings. 
 Although this study examined a number of covariates, it is possible that there are 
unknown or additional variables that might impact adherence and treatment outcomes in 
this population.  Examples might include level of education, social support, quality of 
life, number of previous antiretroviral regimens, presence of ARV resistance, and 
participation in a clinical drug study.  Adherence education and counseling provided by 
case managers in the community may also have an effect on pharmacy refill adherence, 
self-reported adherence and treatment outcomes. 
The short time of follow-up may have limited the ability to measure the long-
range effect of the SAI.  Although the relatively short follow-up time in this study may be 
inadequate to fully appreciate the virologic and immunologic response to therapy, 
extending the study period might result in additional confounders.  For example, the 
population utilizing this public clinic is often transient, incarcerated and often lost to 
follow-up.  
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This study examined multiple variables that could impact both treatment response 
and adherence.  It is difficult to attribute the true effect of each variable.  Future study 
using path analysis might elucidate the true effect of each covariate. 
Three types of antiretroviral therapy were considered in this study: (1) non-
nucleoside reverse transcriptase based; (2) protease inhibitor based; and (3) triple 
nucleoside reverse transcriptase based.  The protease inhibitor (PI) ritonavir is frequently 
administered in a low-dose along with a primary PI as a pharmacokinetic booster to the 
primary PI.  Boosting a PI with ritonavir increases drug exposure and prolongs the 
plasma half-life of the primary protease inhibitor.  This allows for reduced dosing 
frequency and pill burden and may improve overall adherence to the regimen (National 
Institutes of Health, 2006).   Ritonavir-boosting was not assessed in this study and may 
be an important characteristic to assess in future studies since boosting can improve 
adherence through reduced pill burden and greater drug exposure could result in 
improved virologic and immunologic treatment response outcomes.   Nelfinavir is the 
only protease inhibitor that cannot be effectively boosted by ritonavir (Bartlett & Gallant, 
2005).  Since a number of subjects received nelfinavir as a component of HAART, it may 
be helpful to study both boosted and unboosted PI-based regimens. 
 This study included patients who only used one consistent pharmacy to obtain 
their medication.   A large number of patients (n=569) used alternative pharmacies 
throughout the community. Although the demographic characteristics of this population 
are similar to the sample of patients in the usual care group, the pharmacy refill 
adherence rates are not known.  Future studies should consider investigating the 
pharmacy refill rates at community pharmacies to investigate whether there are any 
   
 
 
 
124
unique features from the on-site pharmacy compared to community pharmacies.   Since 
the dedicated on-site pharmacy is used to providing adherence messages within general 
conversation with patients, it is theoretically possible that even this communication may 
have an effect on patient adherence to medication therapy.  It is not known what type of 
adherence messages or encouragement is provided by community pharmacies. 
There was little effect on adherence related to active substance abuse and mental 
health disorders despite literature which supports a negative impact on adherence.  The 
lack of effect in this study may be related to the coding of the substance abuse and mental 
health diagnoses or the small sample size. The covariates related to mental health and 
substance abuse were based on healthcare provider coding and documentation in the 
medical record.  There were no clearly defined objective or operational definitions related 
to these diagnoses. It is possible that these diagnoses were under-diagnosed, over-
diagnosed or misdiagnosed. 
Significance 
This study demonstrates a significant effect on self-reported adherence, pharmacy 
refill adherence, and HIV RNA response associated with participation in the AIDS drug 
assistance program.  There are potential unknown covariates that may be involved with 
adherence and future qualitative inquiry may be helpful in identifying them and their 
potential effect on adherence.  This will be discussed in another section. 
Funding for AIDS Drug Assistance Programs is provided by the federal 
government and often supplemented with individual state funds.  With limited national 
and state funding for these programs, it is imperative that funds be used as effectively as 
possible to serve the greatest number of clients possible and to produce the most optimal 
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clinical outcomes.  This study demonstrates significant improvement in medication 
adherence as well as treatment outcomes associated with participation in one ADAP and 
can serve as a model to local, regional and national programs as a potential means to 
optimize medication adherence and treatment response with limited resources.  
In the State of Florida, a centralized database contains administrative and clinical 
data related to each ADAP participant including CD4 lymphocyte counts, HIV RNA 
results, antiretroviral specific information and sociodemographic information.  The 
findings from this study can serve as a starting point for program administrators to 
analyze statewide data to identify treatment response rates and program effectiveness.  
Additionally, administrators could utilize this database to identify problematic areas or 
areas that may need additional resources based on observation of clinical outcomes as 
measured by CD4 lymphocyte and HIV RNA response.  
Ongoing discussion is occurring on a national level related to the collection and 
study of clinical outcome data from the various AIDS Drug Assistance Programs within 
the United States. This study demonstrates the potential benefit from examining these 
types of data and the potential benefits for program administrators, clinicians and 
patients.   
 Components of the structured adherence program may be appropriate for settings 
with limited technology or limited resources.  Closely monitoring pharmacy refills and 
proactively implementing communication with patients before they run out of medication 
may be quite appropriate for rural or even sites in the developing world in an effort to 
improve adherence and treatment outcomes. 
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 This study contributes to our knowledge of the difficulties in fully understanding 
the patient-level determinants of ARV medication adherence.  There are numerous 
variables that affect adherence and ongoing research is indicated to continue to increase 
our understanding of this complex process.  Results of this study provide a foundation for 
future research exploring issues of medication adherence, pharmacy refill adherence, and 
participation in structured medication access program. 
It is important that the findings from this study are communicated to local staff 
involved in the study as well as the administrators at the regional, state and national level.  
The findings clearly support better adherence and clinical outcomes in the population 
participating in the medication access program.  By disseminating this information to 
clinicians and administrators, others may be encouraged to implement similar procedures 
for monitoring pharmacy refills and initiating structured treatment intervention.  With 
hundreds of medication access programs across the United States, it is important for 
clinicians and administrators to recognize the potential impact of their programs on 
adherence and treatment response.  
Several immediate plans are in process to disseminate the findings of this study.  
Locally, the staff associated with the study site will be informed of the findings.  On a 
community level, attendees at the local Association of Nurses in AIDS Care meeting will 
be provided with an overview of the study and its findings.  At a regional level, the study 
results will be presented to a coalition of government representatives, corporations and 
community advocates representing fourteen southern states and their respective ADAPs.  
Lastly, the study will be submitted for publication in peer-reviewed journal. 
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Implications for Nursing Practice 
The findings of this study support the ability of a structured adherence 
intervention within a medication access program to effectively influence clinical 
outcomes and adherence associated with the treatment of HIV-infected patients.  Nurses 
and other healthcare providers play a key role in providing ongoing education related to 
ARV medication including proper administration, management of medication side 
effects, adherence to therapy, and adherence to clinical care.  Nurses are in a key role to 
formally and informally assess adherence and to refer patients for specialized adherence 
education and counseling as needed.   Nurses often have more contact with the patient 
than any other member of the health care team and are in a pivotal position to assess 
adherence and implement creative strategies to improve adherence and increase 
knowledge. 
Nurses should have strong interviewing skills to be able to elicit information 
regarding adherence in a professional and nonjudgmental manner.  Nurses are in a key 
role to recognize nonadherence and initiate appropriate adherence interventions as 
quickly and effectively as possible.   
Nurse practitioners (NPs) continue to serve as primary care providers for many 
patients with HIV infection and are instrumental in initiating and managing antiretroviral 
therapy.   By providing thorough patient education, selection of tolerable agents that the 
patient is able to adhere to, and prompt referral to adherence specialists, NPs can 
influence adherence in a positive and proactive manner.  Nurse researchers are active in 
adherence research and continue to contribute to this growing body of knowledge.   
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There continues to be an ongoing need to develop effective adherence 
interventions and to increase awareness related to the importance of medication 
adherence among patients living with HIV disease.  It is important to find adherence 
interventions that are cost-effective and replicable outside of a research setting.    
It is equally important to encourage ongoing educational activities for patients, 
nurses, and other health care providers to increase their knowledge and awareness related 
to medication adherence and pharmacy refill adherence as a means to improve 
immunologic and virologic success with HAART. 
There is a growing need for effective patient education regarding readiness for 
treatment, HIV illness management, drug-drug interactions, potential drug side effects 
and side effect management.  The complexity of treatment and the side effects of 
treatment make this an important area for nursing practice.  Similarly, there is a need for 
further development of a standardized definition of adherence and valid objective 
measures of adherence that are appropriate for both clinical research and clinical care 
settings.  Future research needs to address the best method to assess adherence to ensure 
reliability and validity, since this is the crucial outcome measure in all adherence research 
and because adherence has a direct impact on patient morbidity and mortality.  The self-
report method of measuring adherence may not be the most useful predictor of adherence.   
Recommendations for Future Study 
 Based upon the review of related studies and the findings from this study, a 
number of recommendations are made for future research in this area.  This study could 
be replicated using a prospective design with a larger sample size that encompasses 
different geographic areas and which follows subjects for a longer time period. This 
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would generate findings that would be more representative of the population with HIV 
and AIDS and would have the power to more accurately measure the effects of covariates 
associated with adherence and treatment response.  It would be helpful to measure HIV 
RNA response and CD4 count response as a continuous variable over many months to 
many years.  Inclusion of CD4 lymphocyte percentage may be an additional variable to 
consider in the study.  A longitudinal study design might permit longer follow-up to 
determine if adherence and treatment outcome responses are retained for long periods of 
time. 
Future studies should consider distinguishing between ritonavir boosted protease 
inhibitor based regimens and non-ritonavir boosted PI regimens.  Although non-boosted 
PI regimens are becoming less common, there were a significant amount of nelfinavir 
based regimens in the study (non-boosted).  Non-boosted PI regimens are traditionally 
less potent and durable that boosted-PIs and may have less favorable treatment outcomes. 
While this study defined three types of antiretroviral therapy regimens (non-nucleoside 
reverse transcriptase based, protease inhibitor based, and triple nucleoside reverse 
transcriptase based), future studies should consider incorporating newer regimens that 
emerged in 2007 and 2008 including entry inhibitor based, integrase inhibitor based, and 
second generation NNRTI-based. 
A qualitative research component would be very useful in future research.  
Qualitative inquiry may help to identify perceptions and behaviors associated with the 
SAI, other adherence strategies used by patients (such as cellular phone alarms, internet 
based systems, and other personal strategies), factors identified by the clinical population 
to be important in their adherence to medications, and the burden of chronic disease.  
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Qualitative inquiry involving staff of both the medication access program and pharmacy 
may also generate findings that influence adherence such as adherence messages 
delivered within the normal course of business communication, informal teaching 
messages, and other verbal and nonverbal messages. 
Ongoing research in this field should include the study of clients that use 
community pharmacies as well as those that use pharmacies that deliver monthly 
medications directly to patients’ homes.  General community pharmacies (as opposed to 
community HIV-specialty pharmacies) may not be as knowledgeable about HIV 
treatment agents and may not understand the importance of high levels of adherence to 
medication refills.  More pharmacies are offering free home delivery of HIV medications  
as a means to increase their business while providing a valuable service and convenience 
to patients.   The adherence implications of these services have not been formally studied 
and published.  
It is also important to consider the effect of community-based adherence 
educators on patient adherence and treatment outcomes.  Although these programs are 
often funded by Ryan White Grant funding, they frequently operate with case 
management and social work agencies with little or no contact with medical care 
providers, AIDS drug assistance programs, and client pharmacies.  Qualitative studies of 
these programs may provide important information that impact clinical care and 
pharmacy refill behaviors.  As the population affected by HIV continues to impact more 
people of color and more minorities, it is important to consider the potential impact of 
cultural barriers and language barriers of subjects whose primary language is non-
English. 
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While the findings of this study demonstrate improved adherence and treatment 
response associate with the ADAP, it would be beneficial to investigate the costs 
associated with the program and determine if the program is indeed cost-effective for the 
adherence and outcome benefits associated with the program.  With dwindling federal 
and state funding of these programs, this information is critical in ensuring ongoing 
funding of these valuable programs.    
Summary 
The purpose of this retrospective comparative study was to better understand the 
effects of an existing antiretroviral access program on adherence to HAART and response 
to treatment compared to usual care. In the structured adherence intervention (SAI) 
providers closely monitored monthly HIV medication refills and provided structured 
adherence intervention when indicated.  Patients receiving usual care were enrolled in a 
Medicaid-funded medication access program and did not receive ongoing medication 
refill monitoring and structured adherence intervention.  Both patient groups received 
their ARV medications and outpatient HIV medical care from a single treatment center 
and pharmacy 
Three of the four hypotheses were confirmed in this study.  Patients participating 
in the SAI demonstrated higher levels of both self-reported and pharmacy refill adherence 
compared to patients receiving usual care.  Patients in the SAI were almost four times 
more likely to self-report > 90% adherence (OR 3.94, p<.0005) compared to the usual 
care group and almost twice as likely to achieve favorable pharmacy refill adherence (OR 
1.83, p=.005).    Although patients participating in the SAI program demonstrated better 
virologic (HIV RNA) responses to HAART compared to patients receiving usual care, 
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immunologic (CD4 lymphocyte) responses to HAART were not significantly different 
compared to subjects in the usual care program. Patients in the SAI were more than four 
times as likely to achieve a favorable HIV RNA response compared to those in the SAI 
(OR=4.57, p<.0005). 
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